Document:

EX-4.2

 Exhibit 4.2 

Execution Version 

KODIAK SCIENCES INC. 

INVESTORS’ RIGHTS AGREEMENT 

THIS INVESTORS’ RIGHTS AGREEMENT (this
“Agreement”) is made and entered into as of September 8, 2015, by and among KODIAK SCIENCES INC., a Delaware
corporation (the “Company”), and each of the stockholders of the Company that has delivered a signature page hereto (the “Investors”). 

RECITALS 

WHEREAS, concurrently with the execution of this Agreement, the Company and certain of the
Investors (the “Purchasers”) are entering into a Series B Preferred Stock Purchase Agreement (the “Purchase Agreement”) pursuant to which the Company will issue and sell to the Purchasers shares of the
Company’s Series B Preferred Stock, and the Purchasers will purchase such shares of Series B Preferred Stock on the terms and subject to the conditions set forth in the Purchase Agreement; 

WHEREAS, the Company’s and the Purchasers’ respective obligations under the Purchase
Agreement are conditioned upon the execution of this Agreement as set forth herein; and 
 WHEREAS,
in connection with the conversion of the Company from a limited liability company to a corporation, the Company desires to give the holders of the Company’s Series A Preferred Stock certain rights hereunder. 

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual covenants
and agreements herein contained, the parties hereto agree as follows: 
  

	1.	Definitions. 

 “1933 Act” means the Securities Act of 1933, as
amended. 
 “1934 Act” means the Securities Exchange Act of 1934, as amended. 

“Affiliate” means, with respect to any Person, any other Person that, directly or indirectly, controls, is controlled
by, or is under common control with such Person. 
 “Certificate” means the Company’s Certificate of
Incorporation, as amended from time to time. 
 “Common Stock” means the Company’s common stock, par value
$0.0001 per share. 
 “Conversion Securities” means (i) any Common Stock held by an Investor, (ii) any
Common Stock issuable or issued upon conversion of the Preferred Stock now held or hereafter acquired by an Investor or as a dividend or other distribution with respect to, in exchange for, or in replacement of the Preferred Stock now held or
hereafter acquired by an Investor, (iii) any Common Stock issuable or issued upon exercise of any warrants to purchase Common Stock (or exercise and conversion of warrants to purchase Preferred Stock) held by an Investor or as a distribution
with respect to, in exchange for, or in 

 replacement of any warrants to purchase Common Stock (or Preferred Stock) held by an Investor,
and (iv) any Common Stock issued as a dividend or other distribution with respect to, in exchange for, or in replacement of any of the Common Stock that constitutes Conversion Securities pursuant to (i), (ii) and (iii) above. 

“Form S-1,” “ Form
S-3,” “Form S-4” and “Form S-8” mean such respective forms under the
1933 Act, as in effect on the date hereof or any successor registration forms to Form S-1, Form S-3, Form S-4 and Form S-8, respectively, under the 1933 Act subsequently adopted by the U.S. Securities and Exchange Commission (the “SEC”) that, with respect to Form S-3,
Form S-4 and Form S-8, permit (with the exception of Form S-4, in the case of any offering registered thereon) incorporation of
substantial information by reference to other documents filed by the Company with the SEC. 
 “GAAP” means generally
accepted accounting principles in the United States of America. 
 “Holder” means any Investor owning Registrable
Securities (as defined below) or any assignee thereof in accordance with Section 2(m) hereof. 

“Immediate Family” means, with respect to any natural person, each of such person’s spouse, father, mother,
brothers, sisters, aunts, uncles, nieces and nephews and lineal descendants and ancestors. 
 “IPO” means the
Company’s first sale of Common Stock in a public offering pursuant to a registration statement under the 1933 Act and in connection with which shares of Common Stock are admitted to trading on an internationally recognized stock market or
quotation system. 
 “New Securities” means equity securities of the Company, whether now or hereafter authorized, or
rights, options or warrants to purchase said equity securities, or securities of any type whatsoever that are, or may become, convertible into or exchangeable (directly or indirectly) into or exercisable for said equity securities. 

“Person” means any individual or entity. 

“Preferred Stock” means the Company’s preferred stock authorized, issued and outstanding from time to time. 

“Qualified IPO” means the Company’s first sale of Common Stock in a firm commitment underwritten public offering
pursuant to a registration statement under the 1933 Act at a per share public offering price (prior to underwriter commissions and expenses) of at least $10.00 (as adjusted for stock splits, combinations, dividends and the like) and that results in
aggregate gross cash proceeds to the Company of an amount equal to or greater than $75,000,000 (before deduction of underwriting discounts, commissions and expenses). 

  
 -2- 

 “Register,” “registered” and
“registration” refer to a registration effected by preparing and filing a registration statement or similar document in compliance with the 1933 Act, and the automatic effectiveness or the declaration or ordering of
effectiveness of such registration statement or document. 
 “Registrable Securities” means any Conversion
Securities; excluding in all cases, (i) any shares previously sold pursuant to a registered public offering or pursuant to an exemption from the registration requirements of the 1933 Act under which the transferee does not receive
“restricted securities,” (ii) any shares otherwise sold by a person in a transaction in which his, her or its rights under Section 2 are not assigned pursuant to Section 2(m), and
(iii) any shares for which the registration rights have terminated pursuant to Section 2(o). 
 A
“Subsidiary” of any Person means another Person, an amount of the voting securities, other voting ownership or voting partnership interests of which is sufficient to elect at least 50% of its board of directors or other
governing body (or, if there are no such voting interests, 50% or more of the equity interests of which) is owned directly or indirectly by such first Person. 
  

	2.	Registration Rights. 

 (a) Request for Registration. 

(1) If the Company shall receive at any time following the earlier of December 31, 2020 or 180 days after the effective date of the IPO, a
written request from one or more Holders holding at least 50% of the Registrable Securities (on an as-converted into Common Stock basis) (the Holders initiating such request, the “Initiating
Holders”) that the Company effect the registration under the 1933 Act of Registrable Securities with an anticipated aggregate offering price of at least $30,000,000, then the Company shall: 

(i) within ten (10) days of the receipt thereof, give written notice of 

such request to all Holders, 
 (ii) subject to
the limitations of this Section 2(a), use its commercially reasonable efforts to effect a registration under the 1933 Act of all of such Initiating Holders’ Registrable Securities as are specified in such request,
together with all of the Registrable Securities of any other Holder or Holders joining in such request as are specified in a written request given within twenty (20) days after receipt of such written notice from the Company as soon as
practicable, and 
 (iii) file, as promptly as reasonably practicable following receipt of such request of the Initiating Holders in all
other cases, a registration statement under the 1933 Act covering all the Registrable Securities that the Holders shall in writing request to be included in such registration and to use its commercially reasonable efforts to have such registration
statement declared effective. 

  
 -3- 

 (2) If the Initiating Holders intend to distribute the Registrable Securities covered by their
request by means of an underwriting, they shall so advise the Company as part of their request made pursuant to this Section 2(a) and the Company shall include such information in the written notice referred to in
Section 2(a)(i). In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such
Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed upon by the Company, Initiating Holders holding or having the right to receive at least a majority of the Registrable Securities that all Initiating Holders
own or have the right to receive, and such Holder) to the extent provided herein. All parties proposing to distribute their securities through such underwriting shall (together with the Company as provided in
Section 2(d)(5)) enter into an underwriting agreement in customary form with the underwriter or underwriters selected for such underwriting by the Board of Directors of the Company (the “Board”) and
reasonably acceptable to a majority in interest of the Holders. Notwithstanding any other provision of this Section 2(a), if, in the case of a registration requested pursuant to Section 2(a), the
underwriter advises the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise the Company and all Holders of Registrable Securities which
would otherwise be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated pro rata among all Holders thereof desiring to participate in such underwriting (proportionate to
the number of Registrable Securities then held by each such Holder). No Registrable Securities requested by any Holder to be included in a registration pursuant to Section 2(a) shall be excluded from the underwriting unless
all securities other than Registrable Securities are first excluded (including any securities to be offered by the Company). To facilitate the allocation of shares in accordance with the above provisions, the Company or the underwriter may round the
number of shares allocated to any Holder to the nearest 100 shares. 
 (3) Notwithstanding the foregoing provisions of this
Section 2(a), the Company shall not be obligated to effect, or take action to effect any registration pursuant to Section 2(a) after the Company has already effected two registrations initiated by
the Holders pursuant to Section 2(a); provided, however, that no registration of Registrable Securities that shall not have become and remained effective in accordance with
Section 2(d) shall be deemed to be a registration for any purpose of this Section 2(a) unless such registration was withdrawn at the request of the Holders except under the circumstances described in the last clause of
the first sentence of Section 2(f). 
 (4) Notwithstanding the foregoing provisions of this
Section 2(a), in the event that the Company is requested to file any registration statement pursuant to this Section 2(a), the Company shall not be obligated to effect the filing of such
registration statement: 
 (i) during the 90-day period following the effective date of any other
registration statement on Form S-1 or S-3 pertaining to an underwritten public offering of securities for the account of the Company or any Holder; or 

  
 -4- 

 (ii) in any particular jurisdiction in which the Company would be required to execute a general
consent to service of process in effecting such registration, unless the Company is already subject to service in such jurisdiction and except as may be required under the 1933 Act; or 

(iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Section 2(c) below; or 
 (iv) if the
Registrable Securities to be included in the registration statement could be sold without restriction of any manner under Rule 144 of the 1933 Act within a 90-day period and the Company is currently subject to
the periodic reporting requirements of Sections 12(g) or 15(d) of the 1934 Act; or 
 (v) if the Company shall furnish to the Holders
requesting such registration statement a certificate signed by the Chief Executive Officer of the Company stating that, in the good faith judgment of the Board (as evidenced by a written resolution of the Board), it would not be in the best
interests of the Company and its stockholders generally for such registration statement to be filed or to remain effective as long as such registration statement would otherwise be required to remain effective, the Company shall have the right to
defer such filing for a period of not more than 180 days after receipt of the request for registration from the applicable Initiating Holders; provided, however, that the Company may not utilize the right set forth in this
Section 2(a)(4)(v) more than once in any twelve-month period. 
 (b) Company Registration. If after the
closing of the IPO the Company proposes (but without any obligation to do so) to register (including for this purpose a registration effected by the Company for stockholders other than the Holders) any of its capital stock or other equity securities
(or securities convertible into equity securities) under the 1933 Act in connection with the public offering of such securities (other than a registration on Form S-8 relating solely to the sale of securities
to participants in a Company stock plan, a registration relating to a transaction described in Rule 145(a) of the 1933 Act, or a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities
that are also being registered or a registration on Form S-4), the Company shall, at such time, promptly give each Holder of any Registrable Securities written notice of such registration. Upon the written
request of any such Holder, given within ten (10) days after mailing of such notice by the Company, the Company shall, subject to the provisions of Section 2(h) and the following sentence of this
Section 2(b), use its commercially reasonable efforts to cause a registration statement covering all of the Registrable Securities that each such Holder has requested to be registered to become effective under the 1933 Act.
The Company shall have the right, in its sole discretion, to terminate or withdraw, and shall otherwise be under no obligation to complete, any offering of its securities it proposes to make under this Section 2(b) and
shall incur no liability to any Holder for its failure to do so, whether or not such Holder has elected to include securities in such registration. The expenses of such withdrawn registration shall be paid by the Company in accordance with
Section 2(f). 

  
 -5- 

 (c) Form S-3 Registration. 

(1) In case the Company shall receive from one or more Holders a written request or requests that the Company effect a registration on Form S-3 (or on any successor form to Form S-3 regardless of its designation) and any related qualification or compliance with respect to all or a part of the Registrable
Securities owned by such Holder or Holders, the Company will: 
 (i) promptly give written notice of the proposed registration, and any
related qualification or compliance, to all other Holders; and 
 (ii) use its commercially reasonable efforts to effect such registration
as soon as practicable, and in any event, to file within ninety (90) days of the receipt of such request a registration statement under the 1933 Act on Form S-3 covering all of the Registrable Securities
which such Holders have requested to be registered and to use its commercially reasonable efforts to have such registration statement become effective, and to effect such qualification or compliance as may be so requested and as would permit or
facilitate the sale and distribution of all or such portion of such Holder’s or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any other Holder or
Holders joining in such request as are specified in a written request given within twenty (20) days after receipt of such written notice from the Company; provided, however, that the Company shall not be obligated to effect any
such registration, qualification or compliance pursuant to this Section 2(c) if: (1) Form S-3 (or any successor form to Form S-3
regardless of its designation) is not available for such offering by the Holders; (2) the aggregate gross proceeds (before deduction of underwriting discounts and commissions) of the Registrable Securities specified in such request is less than
$10,000,000; (3) the Company shall furnish to the Holder or Holders requesting a registration statement pursuant to this Section 2(c) a certificate signed by the Company’s Chief Executive Officer stating that, in the
good faith judgment of the Board (as evidenced by a written resolution of the Board), it would not be in the best interests of the Company and its stockholders generally for such registration statement to be filed, in which event the Company shall
have the right to defer such filing for a period of not more than one hundred eighty (180) days after receipt of the request of such Holder or Holders, provided that such right shall be exercised by the Company not more than once in any twelve
(12)-month period; (4) the Company shall have effected three registrations pursuant to this Section 2(c); or (5) with respect to any particular jurisdiction, the Company would be required to qualify to do business or
to execute a general consent to service of process in effecting such registration, qualification or compliance, unless the Company is already subject to service in such jurisdiction and except as may be required under the 1933 Act; or
(6) during the period ending one hundred eighty (180) days after the effective date of a registration statement filed pursuant to Section 2(a). 

(2) If the Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise
the Company as part of their request made pursuant to this Section 2(c) and the Company shall include such information in the written notice referred to in Section 2(c)(1)(i). The provisions of
Section 2(a)(2) shall be applicable to such request (with the substitution of Section 2(c) for references to Section 2(a)). 

  
 -6- 

 (d) Obligations of the Company. Whenever required under this
Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably practicable: 

(1) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective, and, upon the request of the Holders of at least a majority of the Registrable Securities registered thereunder, keep such registration statement effective for up to 90 days or until
such earlier time at which the distribution of securities contemplated by such registration statement has been completed (such 90-day or shorter period, the “Effectiveness
Period”); 
 (2) prepare and file with the SEC such amendments and supplements to such registration statement and the
prospectus used in connection with such registration statement, and use its commercially reasonable efforts to cause each such amendment and supplement to become effective, as may be necessary to comply with the provisions of the 1933 Act with
respect to the disposition of all securities covered by such registration statement during the Effectiveness Period; 
 (3) furnish to the
Holders, such number of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements of the 1933 Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable
Securities owned by them; 
 (4) use its commercially reasonable efforts to register or qualify the securities covered by such registration
statement under such other securities or Blue Sky laws of such states and jurisdictions as shall be reasonably requested by the Holders, except that the Company shall not be required in connection therewith or as a condition thereto to
qualify to do business, subject itself to taxation or file a general consent to service of process in any such state or jurisdiction; 
 (5)
in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting
shall also enter into and perform its obligations under such an underwriting agreement, including furnishing an opinion of counsel or entering into a lock-up agreement required pursuant to the provisions of
Section 2(l); 
 (6) notify each Holder covered by such registration statement, at any time when a prospectus
relating thereto covered by such registration statement is required to be delivered under the 1933 Act, of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue
statement of a material fact or omits to state a material fact required to be stated therein or necessary to make 

  
 -7- 

 
the statements therein, in the light of the circumstances under which they were made, not misleading, and promptly file such amendments and supplements which may be required pursuant to
Section 2(d)(2) on account of such event and use its commercially reasonable efforts to cause each such amendment and supplement to become effective; 

(7) use its commercially reasonable efforts to have furnished, at the request of any Holder requesting registration of Registrable Securities
pursuant to this Section 2, if such securities are being sold through underwriters, to such underwriters on the date that such Registrable Securities are delivered to the underwriters for sale in connection with a
registration pursuant to this Section 2: (i) an opinion or opinions, dated such date, of the counsel representing the Company for the purposes of such registration, in form and substance as is customarily given by company
counsel to the underwriters in an underwritten public offering, addressed to the underwriters, if any, and (ii) a “comfort” letter dated such date, from the independent certified public accountant of the Company, in form and substance
as is customarily given by independent certified public accountants to underwriters in an underwritten public offering, addressed to the underwriters, if any; 

(8) apply for listing and use its commercially reasonable efforts to list the Registrable Securities being registered on any national
securities exchange on which a class of the Company’s equity securities is then listed (or in the case of a registration pursuant to Section 2(a), such national securities exchange as is requested by the Initiating Holders
and agreed to by the Company); 
 (9) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such
registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; 

(10) after such registration statement becomes effective, notify each selling Holder in writing of any request by the SEC that the Company
amend or supplement such registration statement or prospectus; 
 (11) provide a transfer agent and registrar for all Registrable Securities
registered pursuant hereto and a CUSIP number for all such Registrable Securities, in each case not later than on the effective date of such registration; 

(12) notwithstanding any other provisions of this Agreement, from and after the time a registration statement filed under this
Section 2 covering Registrable Securities is declared effective, the Company shall have the right to suspend the registration statement and the related prospectus in order to prevent premature disclosure of any material non-public information related to corporate developments by delivering notice of such suspension to the Holders, provided, however, that the Company may exercise the right to such suspension only once
in any consecutive twelve (12) month period and for a period not to exceed ninety (90) days. From and after the date of a notice of suspension under this Section 2(d)(12), each Holder agrees not to use the registration statement or
the related prospectus for resale of any Registrable Security until the earlier of (1) notice from the Company that such suspension has been lifted or (2) the ninetieth (90) day following the giving of the notice of suspension; and 

  
 -8- 

 (13) without in any way limiting the types of registrations to which this
Section 2 shall apply, in the event that the Company shall effect a “shelf registration” on Form S-1 or Form S-3 under Rule 415
promulgated under the 1933 Act, the Company shall take all reasonable action, including, without limitation, the filing of post-effective amendments, to permit the Holders to include their Registrable Securities in such registration in accordance
with the terms of this Section 2. 
 (e) Furnish Information. It shall be a condition precedent to the
obligations of the Company to take any action pursuant to this Section 2 in respect of the Registrable Securities of any selling Holder that such selling Holder shall furnish to the Company such information regarding
itself, the Registrable Securities and the intended method of disposition of such securities, as shall be reasonably requested by the Company in connection with registration of its Registrable Securities. 

(f) Expenses of Demand Registration. All expenses other than underwriters’ or brokers’ discounts and commissions relating to
Registrable Securities incurred in connection with each registration, filing or qualification pursuant to Section 2(a), including (without limitation) all registration, filing and qualification fees, printing and accounting
fees, fees and disbursements of counsel for the Company, and the reasonable fees and disbursements of one counsel for the selling Holders (up to a maximum amount of $50,000), shall be borne and paid by the Company; provided, however,
that the Company shall not be required to pay for any expenses of any registration begun pursuant to Section 2(a) if the registration request is subsequently withdrawn at any time at the request of the Holders of a majority
of the Registrable Securities to be registered in such registration (in which case all participating Holders shall bear such expenses pro rata in accordance with the number of Registrable Securities that were to be registered thereunder by each such
Holder), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one demand registration pursuant to Section 2(a). All underwriters’ and brokers’ discounts and commissions
relating to Registrable Securities included in any registration effected pursuant to Section 2(a) will be borne and paid ratably by the Holders of such Registrable Securities. 

(g) Expenses of Company Registration and Form S-3 Registration. The Company shall bear and pay
all expenses incurred in connection with any registration, filing or qualification of Registrable Securities with respect to any registration pursuant to Section 2(b) or Section 2(c) for each
Holder including, without limitation, all registration, filing and qualification fees, printing and accounting fees, fees and disbursements of counsel for the Company and the reasonable fees and disbursements of one counsel for the selling Holders
(up to a maximum amount of $20,000). Underwriters’ and brokers’ discounts and commissions relating to Registrable Securities included in any registration effected pursuant to Section 2(b) or
Section 2(c) will be borne and paid ratably by the Holders of such Registrable Securities on the basis of the number of Registrable Securities registered on their behalf. 

  
 -9- 

 (h) Underwriting Requirements in Company Registration. In connection with any offering
involving an underwriting of securities being issued by the Company, the Company shall not be required under Section 2(b) to include any of the Holders’ securities in such underwriting unless such Holders accept the
terms of the underwriting as agreed upon between the Company and the underwriters selected by it, and then only in such quantity, if any, as the underwriters determine in their sole discretion, marketing factors allow. If the managing underwriter
for the offering shall advise the Company in writing that the total amount of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the amount of securities to be sold other than by the
Company that marketing factors allow, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the managing underwriter believes marketing factors allow (the
securities so included to be reduced as follows: (a) all securities which stockholders other than the Company and the Holders seek to include in the offering shall first be excluded from the offering to the extent limitation on the number of
shares included in the underwriting is required, and (b) if further limitation on the number of shares to be included in the underwriting is required, then the number of shares held by the Holders that may be included in the underwriting shall
be reduced pro rata in accordance with the number of Registrable Securities held by each such Holder at the time of such offering, but in no event shall the amount of securities of the selling Holders included in the offering be reduced below 25% of
the total amount of securities included in such offering, other than the Company’s IPO in which case the number of shares held by the Holders that may be included in the underwriting may be cut back to zero). For purposes of the preceding
parenthetical concerning apportionment, for any selling stockholder that is a Holder of Registrable Securities and that is a venture capital fund, a partnership, a limited liability company or a corporation, the affiliated venture capital funds,
partners, retired partners, members, retired members and stockholders of such Holder, or the estates and family members of such partners, retired partners, members and retired members and any trusts for the benefit of any of the foregoing persons
shall collectively be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate amount of shares carrying registration rights owned by all entities
and individuals included in such “selling Holder,” as defined in this sentence. 
 (i) Delay of Registration. No Holder
shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this
Section 2. 
 (j) Indemnification. In the event any Registrable Securities are included in a registration
statement under this Section 2: 
 (1) To the extent permitted by law, the Company will indemnify and hold harmless
each Holder, the officers, directors, partners, members, agents and employees of each Holder, legal counsel and accountants for each such holder, any underwriter (as defined in the 1933 Act) for such Holder and each person, if any, who controls such
Holder or underwriter or other aforementioned person within the meaning of the 1933 Act or the 1934 Act, against any losses, claims, damages or liabilities (joint or several) to which they may become subject under the 1933 Act, the 1934 Act or any
other federal or state law, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (each a “Violation”):
(i) any untrue statement or 

  
 -10- 

 
alleged untrue statement of a material fact contained in such registration statement, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements
thereto, any issuer information (as defined in Rule 433 of the 1933 Act) filed or required to be filed pursuant to Rule 433(d) under the 1933 Act, (ii) the omission or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances in which they were made in the case of any prospectus, not misleading, or (iii) any violation or alleged violation by the Company of the 1933 Act, the 1934 Act,
any state or federal securities law or any rule or regulation promulgated under the 1933 Act, the 1934 Act or any state or federal securities law in connection with any matter relating to such registration statement. The Company will promptly
reimburse each such Holder, officer, director, partner, member, agent, employee, legal counsel, accountants, underwriter or controlling person for any legal or other expenses reasonably incurred by them in connection with investigating or defending
any such loss, claim, damage, liability, or action, as incurred. The indemnity agreement contained in this Section 2(j)(1) shall not apply to amounts paid in settlement of any loss, claim, damage, liability or action if
such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld, conditioned or delayed), nor shall the Company be liable to a Holder in any such case for any such loss, claim, damage, liability or
action to the extent that it arises out of or is based upon (i) a Violation that occurs in reliance upon and in conformity with written information furnished to the Company expressly for use in such registration by or on behalf of such Holder
or (ii) in the case of a sale directly by a Holder of Registrable Securities (including a sale of such Registrable Securities through any underwriter retained by such Holder engaging in a distribution solely on behalf of such Holder), an untrue
statement or alleged untrue statement or omission or alleged omission that was contained in a preliminary prospectus and corrected in a final, amended or supplemented prospectus (including a free writing prospectus) delivered to such Holder or
underwriter a reasonable period of time prior to the time of such sale, and such Holder or underwriter failed to deliver a copy of such final, amended or supplemented prospectus (including a free writing prospectus) at or prior to the time of sale
of the Registrable Securities to the person asserting any such loss, claim, damage or liability in any case in which the delivery of such final, amended or supplemented prospectus (including a free writing prospectus) would have eliminated such
loss, claim, damage or liability. 
 (2) Each Holder that includes any Registrable Securities in any registration statement will furnish to
the Company in writing such information as the Company reasonably requests for use in connection with any registration statement or prospectus and agrees to indemnify and hold harmless the Company, each of its directors, each of its officers who
have signed the registration statement, each person, if any, who controls the Company within the meaning of the 1933 Act, each other selling Holder and each person, if any, who controls a selling Holder within the meaning of the 1933 Act against any
losses, claims, damages, or liabilities (joint or several) to which the Company or any such director, officer, Holder or controlling person may become subject, under the 1933 Act, the 1934 Act or any other federal or state law, insofar as such
losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity with written
information furnished to the Company by or on behalf of such Holder expressly for use in such registration, and each such 

  
 -11- 

 
Holder will promptly reimburse any legal or other expenses reasonably and actually incurred by the Company or any such director, officer, Holder or controlling person in connection with
investigating or defending any such loss, claim, damage, liability, or action, as incurred; provided, however, that the liability of any Holder hereunder shall be limited to the proceeds from the offering received by such Holder (net
of any underwriting discounts, commissions or other selling expenses); and provided, further, that the indemnity agreement contained in this Section 2(j)(2) shall not apply to amounts paid in settlement of any
such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder (which consent shall not be unreasonably withheld, conditioned or delayed), nor, in the case of a sale directly by the Company of its
securities (including a sale of such securities through any underwriter retained by the Company to engage in a distribution solely on behalf of the Company), shall the Holder be liable to the Company in any case in which such untrue statement or
alleged untrue statement or omission or alleged omission was contained in a preliminary prospectus and corrected in a final, amended or supplemented prospectus (including a free writing prospectus), and the Company or such underwriter failed to
deliver a copy of such final, amended or supplemented prospectus (including a free writing prospectus) at or prior to the time of sale of the securities to the person asserting any such loss, claim, damage or liability and the delivery of such
final, amended or supplemented prospectus (including a free writing prospectus) would have eliminated such loss, claim, damage or liability. The obligations of the Holders hereunder are several, not joint. 

(3) Promptly after receipt by an indemnified party under this Section 2(j) of notice of the commencement of any
action (including any governmental action) for which the party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this
Section 2(j), deliver to the indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly
with any other indemnifying party similarly noticed, to assume and control the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties
that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the
indemnifying party would be inappropriate due to actual or potential differing interests, as reasonably determined by either party, between such indemnified party and any other party represented by such counsel in such proceeding. The failure to
deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action, if materially prejudicial to its ability to defend such action, shall relieve such indemnifying party of liability to the indemnified
party under this Section 2(j) to the extent, and only to the extent, of such prejudice. 
 (4) In order to provide
for just and equitable contribution to joint liability under the 1933 Act in any case in which either (i) any indemnified party exercising rights under this Agreement, or any controlling person of any such indemnified party, makes a claim for
indemnification pursuant to this Section 2(j) but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or 

  
 -12- 

 
the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this Section 2(j) provides for
indemnification in such case, or (ii) contribution under the 1933 Act may be required on the part of any such indemnifying party or any such controlling person in circumstances for which indemnification is provided under this
Section 2(j), then, and in each such case, the indemnifying party, in lieu of indemnifying such indemnified party hereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such loss,
liability, claim, damages or expense in such proportion as is appropriate to reflect the relative fault of the indemnifying party on the one hand and the indemnified party on the other hand in connection with the statements or omissions that
resulted in such loss, liability, claim, damages or expense, as well as any other relevant equitable considerations; provided, however, that no contribution by any Holder, when combined with any other amounts paid by such Holder
pursuant to this Section 2(j), shall exceed the aggregate net proceeds received by such Holder in the offering. The relative fault of the indemnifying party and the indemnified party shall be determined by reference to,
among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the indemnifying party or by the indemnified party and the
parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be
entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. Notwithstanding the foregoing, in no event shall such Holder’s liability pursuant to this Section 2(j)(4), when combined
with any amounts paid or payable by such Holder pursuant to Section 2(j)(2), exceed proceeds from the offering received by such Holder (net of any underwriting discounts, commissions or other selling expenses). 

(5) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten offering, the obligations of the
Company and the Holders under this Section 2(j) shall survive the sale, if any, of the Registrable Securities and the completion of any offering of Registrable Securities in a registration statement. 

(k) Reports Under the 1934 Act. With a view to making available to the Holders the benefits of Rule 144 promulgated under the 1933 Act
(“Rule 144”) and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration, and with a view to making it possible for Holders to have the
resale of the Registrable Securities registered pursuant to a registration statement on Form S-3, the Company shall use its commercially reasonable efforts to: 

(i) make and keep adequate public information available, as those terms are understood and defined in Rule 144, at all times after the
effective date of the registration statement for the IPO and for so long as the Company is subject to the periodic reporting requirements under Section 13 or Section 15(d) of the 1934 Act; 

(ii) following the closing of the IPO, take such action, including the voluntary registration of its Common Stock under Section 12 of the
1934 Act or compliance with the reporting requirements of Section 15(D) of the 1934 Act, as is necessary to enable the Holders to utilize Form S-3 for the sale of their Registrable Securities; 

  
 -13- 

 (iii) after the closing of the IPO, file with the SEC in a timely manner all reports and other
documents required of the Company under the 1933 Act and the 1934 Act; and 
 (iv) furnish to any Holder, so long as the Holder owns any
Registrable Securities, forthwith upon request (1) a written statement by the Company as to its compliance with the reporting requirements of Rule 144 (at any time after 90 days after the closing of the IPO), the 1933 Act and the 1934 Act (at
any time after it has become subject to such reporting requirements), or as to its qualification as a registrant whose securities may be resold pursuant to Form S-3 (at any time after it so qualifies), (2) a
copy of the most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company, and 
 (3) such other
documents as may be reasonably requested in availing any Holder of any rule or regulation of the SEC which permits the selling of any such securities without registration or pursuant to such form. 

(l) Lock-up Agreement. 

(1) If requested by the Company and/or any underwriters managing the IPO, each Investor agrees to not, and to enter into a lock-up agreement in the form proposed by the Company and/or the underwriters pursuant to which such Investor will not, (i) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities of the Company convertible into or exercisable or
exchangeable for Common Stock owned by the Investor as of the effective date of the IPO, except the Registrable Securities sold in the IPO, or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of
the economic consequences of ownership of such Common Stock, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash or otherwise, without the prior consent of
the Company or the underwriter, provided that such lock-up time period shall not exceed 180 days from the effective date of the IPO or, if required by such underwriter, such longer period of time as is
necessary to enable such underwriter to issue a research report or make a public appearance that relates to an earnings release or announcement by the Company within 18 days before or after the date that is 180 days after the effective date of the
registration statement relating to such IPO, but in any event not to exceed 198 days following the effective date of the registration statement relating to such IPO; provided further that nothing in this
Section 2(l) shall prohibit, and any lock-up agreement entered into hereunder shall permit, the transfer by a Holder to a member of such Holder’s Immediate Family or to an
Affiliate of such Holder, so long as such transferee also agrees to enter into and be bound by a lock-up agreement substantially identical to the lock-up agreement
required by this Section 2(l). Any such lock up shall not apply to any Common Stock or any other securities purchased by an Investor in the IPO or any time subsequent to the IPO. In order to enforce the foregoing covenant,
the Company may impose stop-transfer instructions with respect to the 

  
 -14- 

 
securities of each Investor (and the shares of securities of every other person subject to the foregoing restriction) until the end of such period. Any underwriter, in connection with an
underwritten offering pursuant to this Agreement, is an intended third-party beneficiary of this Section 2(l) and shall have the right, power and authority to enforce the provision hereof as though it were a party hereto.

 (2) Each Investor agrees that a legend reading substantially as follows shall be placed on all certificates representing the securities of
each Investor to be subject to such lock up (and the shares or securities of every other person subject to the restriction contained in this Section 2(l) until the expiration of the
lock-up period): 
 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A LOCK-UP PERIOD AFTER THE EFFECTIVE DATE OF CERTAIN OF THE ISSUER’S REGISTRATION STATEMENTS FILED UNDER THE SECURITIES ACT, AS MAY BE AMENDED FROM TIME TO TIME, AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY
AND THE ORIGINAL HOLDER OF THESE SECURITIES, AS MAY BE AMENDED FROM TIME TO TIME, A COPY OF WHICH IS ON FILE IN THE OFFICE OF THE SECRETARY OF THE ISSUER. SUCH LOCK-UP PERIOD IS BINDING ON TRANSFEREES OF THESE
SHARES.” 
 (m) Assignment of Registration Rights. The rights to cause the Company to register Registrable Securities pursuant to
this Section 2 may be assigned by any Holder to a “permitted transferee” pursuant to this Section 2(m) and by such transferee to a subsequent permitted transferee, but only if such rights
are transferred with all related obligations hereunder. A “permitted transferee” means (a) (i) an Affiliate of such Holder or transferee, (ii) any member or members of such Holder’s Immediate Family or a trust for the
benefit of any member or members of such Holder’s Immediate Family, if by gift or bequest or through inheritance to, or for the benefit of, such person, (iii) a trust in respect of which such Holder serves as trustee, provided,
however, that the trust instrument governing such trust shall provide that such Holder, as trustee, shall retain sole and exclusive control over the voting and disposition of such rights until the termination of this Agreement, or (iv) a
limited partnership or limited liability company, all partners or members of which are members of such Holder’s Immediate Family, or (b) any person in connection with the sale or other transfer of at least an aggregate of 300,000 shares of
such Holder’s Registrable Securities (as adjusted for stock splits, combinations, stock dividends and recapitalizations). No transfer may be made pursuant to this Section 2(m) to a transferee reasonably determined in
good faith by written resolution of the Board to be, directly or indirectly, a competitor of the Company. In addition, no transfer may be made pursuant to this Section 2(m), unless (A) the intended permitted transferee
to whom rights under this Agreement are transferred shall have, as a condition to such transfer, previously delivered to the Company a written instrument by which such permitted transferee agrees to be bound by the obligations imposed upon Holders
under this Agreement to the same extent as if such transferee were a 

  
 -15- 

 
Holder under this Agreement, (B) within a reasonable amount of time prior to such transfer the Company shall have been furnished with written notice of such transferee’s name and
address, and the securities with respect to which such registration rights are being assigned; and (C) following such transfer, the further disposition of such Registrable Securities by the permitted transferee is restricted under the 1933 Act. 

(n) Limitations on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of the Holders of a majority of the Registrable Securities (assuming for these purposes the conversion of the Registrable Securities into Common Stock), enter into any agreement with any holder or prospective holder of any securities
of the Company relating to registration rights unless such agreement includes: 
 (a) to the extent such agreement would allow such holder or prospective
holder to include such securities in any registration statement filed under Section 2(a), 2(b) or 2(c) hereof, a provision that such holder or prospective holder may include such securities in any such
registration only to the extent that the inclusion of its securities will not reduce the amount of the Registrable Securities of the Holders that would otherwise be included; and (b) a provision preventing such holder or prospective holder from
making a demand for registration. 
 (o) Termination of Registration Rights. 

(1) The registration obligations of the Company pursuant to this Section 2 shall terminate with respect to any Holder
on the first date upon which all of the remaining Registrable Securities then held or issuable to such Holder (together with its Affiliates, partners, members and former partners and former members) could be sold under Rule 144 without restriction.

 (2) All registration obligations of the Company pursuant to this Section 2 shall terminate as to all Holders
three (3) years after the closing date of the Qualified IPO. 
 (3) All registration obligations of the Company pursuant to this
Section 2 shall terminate as to all Holders immediately prior to (i) any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, or (ii) a Change of Control (as such term is
defined in the Certificate). 
  

	3.	Information Rights; No Publicity; IPO Participation Right. 

 (a) Delivery of Financial
Statements; Inspection Rights. 
 (1) The Company will furnish the following reports to each Investor holding at least 1,000,000 shares
of the Company’s Preferred Stock (as adjusted for any share splits, combinations, dividends or the like with respect to such shares) (a “Major Investor”): 

(i) as soon as practicable after the end of each fiscal year of the Company, and in any event within one hundred eighty (180) days
thereafter, a balance sheet of the Company as at the end of such fiscal year and statement of stockholders’ equity as of the end of such year, and statements of income and cash flows of the Company for such year, such year-end financial reports
to be in reasonable detail, prepared in accordance with generally accepted accounting principles (“GAAP”), which will be audited and certified by an independent public accounting firm selected by the Company unless otherwise
determined by the Board; and 

  
 -16- 

 (ii) at least thirty (30) days after the beginning of each fiscal year, an 

annual budget and forecast for such fiscal year, prepared on a quarterly basis. 

(2) The Company shall permit each Major Investor, at such Major Investor’s expense, to visit and inspect the Company’s properties, to
examine its books of account and records and to discuss the Company’s affairs, finances and accounts with its officers, all at such reasonable times as may be requested by the Major Investor. 

(3) The Company shall not be obligated under this Section 3 to provide any information that (i) it deems in good
faith to be a trade secret or similar confidential information or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel, as advised by counsel. 

(b) Termination of Information and Inspection Covenants. The covenants set forth in Section 3(a) shall
terminate and be of no further force or effect immediately prior to the earliest to occur of (i) the closing of the Qualified IPO, (ii) the time when the Company first becomes subject to the periodic reporting requirements of Sections
12(g) or 15(d) of the 1934 Act, or 
 (iii) the consummation of a Change of Control (as such term is defined in the Certificate). 

(c) Confidentiality. Each Investor agrees, severally and not jointly, that such Investor will keep confidential and will not disclose,
divulge or use for any purpose, other than to monitor its investment in the Company, any confidential information obtained from the Company pursuant to the terms of this Agreement or otherwise, and such Investor acknowledges that it will not, unless
otherwise required by law or the rules of any national securities exchange, association or marketplace, disclose such information without the prior written consent of the Company except such information that (i) is known or becomes known to the
public in general (other than as a result of a breach of this Section 3(c) by an Investor), or (ii) is or has been independently developed or conceived by the Investor without use of the Company’s confidential
information. 
 (d) IPO Participation Right. Subject to compliance at the time with all applicable securities laws and regulations,
the Company will use commercially reasonable efforts (which shall include multiple attempts, on multiple dates, with multiple representatives of the managing underwriter(s), including oral and written communications with the most senior underwriter
employees working on the IPO) to cause the managing underwriter(s) of the IPO to provide Baker Bros., provided Baker Bros. is a Major Investor immediately prior to the IPO, on the same terms, including the price per share, and subject to the same
conditions, as are applicable to all other purchasers in the IPO, the option to purchase a number of shares of Common Stock being issued in the IPO equal to up to twenty-five percent (25%) of the total number of shares of Common Stock offered for
sale in the IPO (the “New IPO Shares”). Baker Bros. may elect to allocate such New IPO Shares among the funds which it advises in its sole discretion. 

  
 -17- 

 (e) No Publicity. The Company agrees that it will not, without the prior written consent
of Baker Bros., use in advertising, publicity or marketing communications regarding the Company’s Series B Preferred Stock financing (whether oral or written) or other public communication or filing, the Baker Bros. name or, to the
Company’s knowledge, the name of any partner or employee thereof, nor any trade name, trademark, trade device, service mark, symbol or any abbreviation, or contraction thereof owned by Baker Bros., except that the Company may make any such
disclosure if, upon the advice of counsel, there is no alternative to such disclosure because it is required by applicable law or regulation, and Baker Bros. is notified of such obligation in advance and given reasonable opportunity to minimize such
disclosure. Notwithstanding the foregoing, the Company may disclose the name of Baker Bros. in connection with the provision of any details regarding this Agreement or the Related Agreements (as defined in the Purchase Agreement) and the
transactions contemplated hereby and thereby to any of its executive officers, directors, stockholders, accountants, counsel and financial advisors with a need to know such information, provided that such recipient is notified of the foregoing
confidentiality obligations. 
  

	4.	Preemptive Rights. 

 (a) Content of Preemptive Right. Subject to the terms and
conditions specified in this Section 4 and applicable securities laws, in the event the Company proposes to offer or sell any New Securities, the Company shall first make an offering of such New Securities to each Investor
holding at least 100,000 shares of the Company’s Preferred Stock (as adjusted for any share splits, combinations, dividends or the like with respect to such shares) (a “ROFR Investor”) in accordance with
the provisions of this Section 4. 
 (b) Offer Notice. The Company shall deliver a notice, in
accordance with the provisions of Section 5(a) hereof, (the “Offer Notice”) to each of the ROFR Investors stating (i) its bona fide intention to offer such New Securities, (ii) the number of
such New Securities to be offered, and (iii) the price and terms upon which it proposes to offer such New Securities. 
 (c) Exercise
of Preemptive Right. By written notification received by the Company within ten (10) days after receipt of the Offer Notice, each of the ROFR Investors may elect to purchase or obtain, at the price and on the terms specified in the Offer
Notice, up to that portion of such New Securities which equals the proportion that the number of shares of Common Stock issuable or issued upon conversion of Preferred Stock (and any other securities convertible into, or otherwise exercisable or
exchangeable for, shares of Common Stock) then held by such ROFR Investor bears to the total number of shares of Common Stock of the Company then outstanding (assuming full conversion and exercise of all outstanding convertible and/or exercisable
securities including outstanding options and warrants and including the ungranted option pool provided for in any equity plan established by the Company and approved by the Board) and held by all securityholders of the Company. 

(d) Undersubscription. If all New Securities referred to in the Offer Notice are not elected to be fully purchased or obtained as
provided in Section 4(c), the Company may, during the one hundred fifty (150) day period following the expiration of the period provided in Section 4(c), offer, sell or agree to sell the
remaining unsubscribed portion of such New 

  
 -18- 

 
Securities (collectively, the “Refused Securities”) to any person or persons at a price not less than, and upon terms not materially more favorable to the offeree than,
those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within sixty (60) days after the end of such one hundred fifty
(150) day period, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Investors in accordance with this Section 4. 

(e) Exempt Issuance. The preemptive right in this Section 4 shall not be applicable to the issuance or sale
of: (i) any shares issued pursuant to the Purchase Agreement; (ii) any Excluded Stock, as such term is defined in the Certificate, including any options or rights to subscribe for or purchase Excluded Stock or securities by their terms
convertible into or exchangeable for Excluded Stock or options to purchase or rights to subscribe for or purchase such convertible or exchangeable securities for Excluded Stock; (iii) any securities that, with approval of the Board, are not
offered to any existing stockholder of the Company; (iv) shares as to which the application of this Section 4 is waived by (x) Holders holding a majority of the outstanding Registrable Securities or (y) the
Board. In addition to the foregoing, the preemptive right in this Section 4 shall not be applicable with respect to any ROFR Investor in any offering of New Securities if (A) at the time of such offering, the Investor
is not an “accredited investor,” as such term is defined in Rule 501(a) of Regulation D promulgated under the Securities Act and (B) such offering of the New Securities is otherwise being offered only to accredited investors and/or Persons
other than U.S. Persons (as defined in Rule 902 under the Securities Act). 
 (f) Assignability. The preemptive right set forth in
this Section 4 may not be assigned or transferred except that such right is assignable by each ROFR Investor to any Affiliate of such ROFR Investor. 

(g) Termination. The preemptive right set forth in this Section 4 shall terminate upon the earlier of:
(i) immediately prior to the consummation of the Qualified IPO, or (ii) immediately prior to the consummation of a Change of Control (as such term is defined in the Certificate). The preemptive right set forth in this
Section 4 shall terminate with respect to any ROFR Investor who fails to purchase, in any transaction subject to this Section 4, all of such ROFR Investor’s pro rata amount of the New
Securities allocated (or, if less than such ROFR Investor’s pro rata amount is offered by the Company, such lesser amount so offered) to such ROFR Investor pursuant to this Section 4. Following any such termination,
such ROFR Investor shall no longer be deemed a “ROFR Investor” for any purpose of this Section 4. 
  

	5.	Miscellaneous. 

 (a) Notices. Any notice or other communication required or
permitted to be delivered to any party under this Agreement will be in writing and will be deemed delivered, given and received when delivered (by hand, by registered mail, by courier or express delivery service, by
e-mail or by facsimile) to the address, e-mail address or facsimile telephone number set forth beneath the name of such party below (or to such other address, e-mail address or facsimile telephone number as such party will have specified in a written notice given to the other parties hereto): 

  
 -19- 

	 	(i)	if to the Company: 

 Kodiak Sciences Inc. 

2631 Hanover Street 
 Palo Alto,
California 94304 
 Attention: Victor Perlroth 

E-mail: vperlroth@kodiaksciences.com 

with a copy (which shall not constitute notice) to: 

Jones Day 
 1755 Embarcadero
Road 
 Palo Alto, California 94303 

Attention: David B. SIkes 

Facsimile: (650) 739-3900 
  

	 	(ii)	if to an Investor: 

 To the address, e-mail address or
facsimile telephone number of such Investor indicated on such Investor’s signature page. 
 (b) Entire Agreement. This Agreement
(including the exhibits hereto) and the documents mentioned herein constitute the entire understanding of the parties with respect to the subject matter hereof and thereof and supersede any and all prior understandings and agreements, whether
written or oral, with respect to such subject matter. 
 (c) Amendments, Waivers and Consents. Any term of this Agreement (other than
Section 3 and Section 4) may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only
with the written consent of the Company and the holders of a majority of the shares of Common Stock and Preferred Stock, voting together as a single class, with the Preferred Stock voting on an as-converted
into Common Stock basis. The provisions of Section 3 may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) in a manner that materially decreases the rights of
Major Investors hereunder only with the written consent of the Company and the Major Investors holding a majority of the Registrable Securities that are held by all of the Major Investors. The provisions of Section 4 may be
amended or waived (either generally or in a particular instance and either retroactively or prospectively) only as set forth in Section 4 or with the written consent of the Company and the ROFR Investors holding a majority
of the Registrable Securities that are held by all of the ROFR Investors. Any amendment, termination or waiver effected in accordance with this Section 5(c) shall be binding on all parties hereto (including future
Investors), even if they do not execute such consent. No consent shall be necessary to add additional Persons as signatories to this Agreement, provided that such Persons shall hold or have acquired shares of the Company’s capital stock. 

  
 -20- 

 (d) Binding Effect; Assignment. This Agreement and any amendment or waiver affected in
accordance with Section 5(c) shall be binding upon and inure to the benefit of the personal representatives, successors and permitted assigns of the respective parties hereto. The Company shall not assign this Agreement or
any rights or obligations hereunder without the prior written consent of holders of at least a majority of the Registrable Securities held by Investors. Except with respect to the indemnified persons contemplated by
Section 2(j) who are intended third party beneficiaries of this Agreement and except as otherwise expressly provided for herein, nothing in this Agreement is intended to confer upon any party other than the parties hereto
or their respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement. 
 (e)
Titles and Subtitles. The titles, captions and headings of this Agreement are included for ease of reference only and will be disregarded in interpreting or construing this Agreement. Unless otherwise specifically stated, all references
herein to “Sections” and “Exhibits” will mean “Sections” and “Exhibits” to this Agreement. 
 (f)
Governing Law; Dispute Resolution. This Agreement shall be governed by and construed under the laws of the State of Delaware in all respects as such laws are applied to agreements among Delaware residents entered into and performed entirely
within Delaware, without giving effect to conflict of law principles thereof. The parties agree that any action brought by either party under or in relation to this Agreement, including without limitation to interpret or enforce any provision of
this Agreement, shall be brought in, and each party agrees to and does hereby submit to the jurisdiction and venue of, any state or federal court located in the county where the Company’s principal office is located. 

(g) Severability. In the event that any provision of this Agreement, or the application thereof, becomes or is declared by a court of
competent jurisdiction to be illegal, void or unenforceable, the remainder of this Agreement shall continue in full force and effect and shall be interpreted so as reasonably to effect the intent of the parties hereto. The parties hereto shall use
their commercially reasonable efforts to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that shall achieve, to the extent possible, the economic, business and other purposes of such void or
unenforceable provision. 
 (h) Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same agreement. 
 (i) Specific Performance. The Company recognizes
that the rights of the Holders under this Agreement are unique, and, accordingly, the Holders shall, in addition to such other remedies as may be available to them at law or in equity, have the right to enforce their rights hereunder by actions for
injunctive relief and specific performance to the extent permitted by law. This Agreement is not intended to limit or abridge any rights of the Holders which may exist apart from this Agreement. 

  
 -21- 

 (j) Aggregation of Stock. All shares of Registrable Securities held or acquired by
affiliated entities or persons shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

[Remainder of Page Intentionally Left Blank] 

  
 -22- 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

 

			
	 COMPANY:
  

KODIAK SCIENCES INC.

		
	By:	 	 /s/ Victor Perlroth

	Name:	 	Victor Perlroth
	Title:	 	Chief Executive Officer

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

667, L.P. 
  

					
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to 667, L.P., pursuant to authority granted to it by Baker Biotech Capital, L.P., general partner to 667, L.P., and not as
the general partner.
			
		 		  	
	    	 	By:	  	/s/ Scott L. Lessing                                
		 	Name:	  	Scott L. Lessing
		 	Title:	  	President

 Contact information for notices hereunder: 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

BAKER BROTHERS LIFE SCIENCES, L.P. 
  

					
	By:	 	BAKER BROS. ADVISORS LP, management company and investment adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner
to Baker Brothers Life Sciences, L.P., and not as the general partner.
			
		 		  	
	    	 	By:	  	/s/ Scott L. Lessing                                
		 	Name:	  	Scott L. Lessing
			
		 	Title:	  	President

 Contact information for notices hereunder: 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Matt Altman
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Matt Altman
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 Asia Intelligence Holdings Limited

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Rong Lu

	Investor’s Signature	 		  	Signature
			
		 		  	 Rong Lu

		 		  	Print Name
			
		 		  	 Director

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 John Bedbrook
	 		  	 Bedbrook Survivors Trust

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ John Bedbrook
	 		  	 /s/ John Bedbrook

	Investor’s Signature	 		  	Signature
			
		 		  	 John Bedbrook

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Derek Berry
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Derek Berry
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Jack Cabala
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Jack Cabala
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 John K. Cabala
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ John K. Cabala
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Stephen A. Charles
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Stephen A. Charles
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 David Collet
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ David Collet
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Michelle Hocking De Geest
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Michelle Hocking De Geest 
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 Francois Guy Drouin Revocable Trust Dated Feb 25, 2010

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Francois Drouin, Trustee

	Investor’s Signature	 		  	Signature
			
		 		  	 Francois Drouin, Trustee

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 Jean P Drovin Revocable Trust

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Jean Drovin

	Investor’s Signature	 		  	Signature
			
		 		  	 Jean Drovin

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Karl Englest
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Karl Englest
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 ERNEST J. GALLO 1993 PERSONAL TRUST

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ ERNEST J. GALLO

	Investor’s Signature	 		  	Signature
			
		 		  	 ERNEST J. GALLO

		 		  	Print Name
			
		 		  	 TRUSTEE

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Michael A Fournel
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Michael A Fournel
	 		  	      

	Investor’s Signature	 		  	Signature
			
		 		  	      

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 GC&H Investments, LLC

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Jim Kindler

	Investor’s Signature	 		  	Signature
			
		 		  	 Jim Kindler

		 		  	Print Name
			
		 		  	 Manager

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 [ILLEGIBLE]

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Corey Goodman

	Investor’s Signature	 		  	Signature
			
		 		  	 Corey Goodman

		 		  	Print Name
			
		 		  	 Managing Partner - Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Alan Grayce
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Alan Grayce
	 		  	      

	Investor’s Signature	 		  	Signature
			
		 		  	      

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Nahum Guzik
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Nahum Guzik
	 		  	      

	Investor’s Signature	 		  	Signature
			
		 		  	      

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 Ketchum Capital, LLC

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Karl Englert

	Investor’s Signature	 		  	Signature
			
		 		  	 Karl Englert

		 		  	Print Name
			
		 		  	 Manager

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	                
	Fax:	 	
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Bruce Keyt
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Bruce Keyt
	 		  	      

	Investor’s Signature	 		  	Signature
			
		 		  	      

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	                
	Fax:	 	
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Michael Kiparsky
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Michael Kiparsky
	 		  	      

	Investor’s Signature	 		  	Signature
			
		 		  	      

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	                
	Fax:	 	
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 [ILLEGIBLE]
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 [ILLEGIBLE]
	 		  	      

	Investor’s Signature	 		  	Signature
			
		 		  	      

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	                
	Fax:	 	
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 James Montazee
	 		  	      

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ James Montazee
	 		  	      

	Investor’s Signature	 		  	Signature
			
		 		  	      

		 		  	Print Name
			
		 		  	      

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

 

					
	INVESTOR:
	
	 DUSTIN A. MOSKOVITZ TTEE

DUSTIN A. MOSKOVITZ TRUST DTD 12/27/05

		
	By:	 	 /s/ Jed Clark

		 	Name:	 	Jed Clark
		 	Title:	 	Authorized Signatory

 
					
	
	Contact information for notices hereunder:
		
	Address:	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	  
	 		  	 The O’Brien Family Trust

	Print Investor’s Name	 		  	Name of the Entity
			
	  
	 		  	 /s/ Eric O’Brien

	Investor’s Signature	 		  	Signature
			
		 		  	 Eric O’Brien

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title.
			
	  
	 		  	 John S Osterweis, trustee for the Osterweis Receivable Trust dated 4/13/18

	Print Investor’s Name	 		  	Name of the Entity
			
	  
	 		  	 /s/ John S Osterweis

	Investor’s Signature	 		  	Signature
			
		 		  	 John S Osterweis

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	  
	 		  	 PAUL AND MORCIA COOK LIVING TRUST

	Print Investor’s Name	 		  	Name of the Entity DATED 4-21-92
			
	  
	 		  	 /s/ PAUL M. COOK

	Investor’s Signature	 		  	Signature
			
		 		  	 PAUL M. COOK, TRUSTEE

		 		  	Print Name
			
		 		  	 TRUSTEE

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Paul L Beckman
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Paul L Beckman
	 		  	 /s/ Paul L Beckman/ Linda S Beckman

	Investor’s Signature	 		  	Signature
			
		 		  	 Paul L Beckman/ Linda S Beckman

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 D. Victor Perlroth
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ D. Victor Perlroth
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 MLPF&S FBO Daniel Victor Perlroth
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Victor Perlroth
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Mark G. Perlroth
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Mark G. Perlroth
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Frank Perlroth
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Frank Perlroth
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

 

					
	INVESTOR:
	
	Sarah Nicole Perlroth
		
	By:	 	 /s/ Sarah Nicole Perlroth

		 	Name:	 	Sarah Nicole Perlroth
		 	Title:	 	n/a

 
					
	
	Contact information for notices hereunder:
		
	Address:	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Andrew Raab
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Andrew Raab
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Erik D. Ragatz
	 		  	 Ragatz Revocable Trust Dated 1/9/06

	Print Investor’s Name	 		  	Name of the Entity
			
	  
	 		  	 /s/ Erik D. Ragatz

	Investor’s Signature	 		  	Signature
			
		 		  	 Erik D. Ragatz

		 		  	Print Name
			
		 		  	 TRUSTEE

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	  
	 		  	 Robert L. Morse Jr. and Susan Cleary Morse Trust

	Print Investor’s Name	 		  	Name of the Entity
			
	  
	 		  	 /s/ Robert L. Morse Jr.

	Investor’s Signature	 		  	Signature
			
		 		  	 Robert L. Morse Jr.

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Scott Robertson
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Scott Robertson
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Robert E. Sarafan
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Robert E. Sarafan
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Thomas A.
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Thomas A.
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Marc Saiontz
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Marc Saiontz
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Steven Sanislo
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Steven Sanislo
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 John Schroer
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ John Schroer
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 R. Randolph Scott
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ R. Randolph Scott
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Gregory A. Sissel
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Gregory A. Sissel
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	  
	 		  	 Smith Family Trust

	Print Investor’s Name	 		  	Name of the Entity
			
	  
	 		  	 /s/ Fred Smith

	Investor’s Signature	 		  	Signature
			
		 		  	 Fred Smith

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 David Stack
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ David Stack
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	  
	 		  	 Stanford-StartX LLC

	Print Investor’s Name	 		  	Name of the Entity
			
	  
	 		  	 /s/ Sabrina Liang

	Investor’s Signature	 		  	Signature
			
		 		  	 Sabrina Liang

		 		  	Print Name
			
		 		  	 Director, School & Department Funds

		 		  	Title 

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	     
	 		  	 Steep Rock Capital LTD

	Print Investor’s Name	 		  	Name of the Entity
			
	  
	 		  	 /s/ Paul Swigart

	Investor’s Signature	 		  	Signature
			
		 		  	 Paul Swigart

		 		  	Print Name
			
		 		  	 Director

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written: 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Andrew Stephens
	 		  	 The Stephens Family Trust dated June 13, 2006

	Print Investor’s Name	 		  	Name of the Entity    
			
	 /s/ Andrew Stephens
	 		  	 /s/ Andrew Stephens

	Investor’s Signature	 		  	Signature
			
		 		  	 Andrew Stephens

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	
		
	Attn:	 	
	Fax:	 	
	Email:	 	

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 The Cheng Family Trust

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Wallace Cheng

	Investor’s Signature	 		  	Signature
			
		 		  	 Wallace Cheng and Gretchen Cheng, As Trustees of the Cheng Family Trust dated March 7, 2013

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  
 75 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
	      
	 		  	 Franklin H. Top, Jr. Revocable Inter Vivos Trust, dated 12/3/1991

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Franklin H. Top, Jr.

	Investor’s Signature	 		  	Signature
			
		 		  	 Franklin H. Top, Jr.

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  
 76 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
	  

     
	 		  	  
 Lois E. Top Revocable Inter Vivos
Trust, dated December 3, 1991

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Lois E. Top

	Investor’s Signature	 		  	Signature
			
		 		  	 Lois E. Top

		 		  	Print Name
			
		 		  	 Trustee

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  
 77 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Walt Ordemann 
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Walt Ordemann 
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  
 78 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Trevor Watt
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Trevor Watt 
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  
 79 

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Steven Winch
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Steven Winch
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Peter Van Vlasselaer
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Peter Van Vlasselaer
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Grant Yonehiro
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Grant Yonehiro
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Fan Zhang
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Fan Zhang
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Tony Zheng
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Tony Zheng
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 Masaya LLC

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Carlos Gonzalez 

	Investor’s Signature	 		  	Signature
			
		 		  	 Carlos Gonzalez

		 		  	Print Name
			
		 		  	 Managing Member

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 Macro Biotech LLC

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Carlos Gonzalez 

	Investor’s Signature	 		  	Signature
			
		 		  	 Carlos Gonzalez

		 		  	Print Name
			
		 		  	 Manager

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	      
	 		  	 SEM Biopharm, LLC

	Print Investor’s Name	 		  	Name of the Entity
			
	      
	 		  	 /s/ Rafael Urquia II

	Investor’s Signature	 		  	Signature
			
		 		  	 Rafael Urquia II

		 		  	Print Name
			
		 		  	 Manager

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  

 IN WITNESS WHEREOF, the Company and the
Investors have executed this INVESTORS’ RIGHTS AGREEMENT as of the day and year first above written. 

INVESTOR: 
  

					
	If you are an individual, please print your name and sign below:	 		  	If you are signing on behalf of an entity, print the name of the entity and sign below, indicating your title:
			
	 Ron Glickman
	 		  	  

	Print Investor’s Name	 		  	Name of the Entity
			
	 /s/ Ron Glickman 
	 		  	  

	Investor’s Signature	 		  	Signature
			
		 		  	  

		 		  	Print Name
			
		 		  	  

		 		  	Title

 Contact information for notices hereunder: 
  

			
	Address:            	 	                
		
	Attn:	 	                
	Fax:	 	                
	Email:	 	                

  
 88EX-4.3

 Exhibit 4.3 

EXECUTION VERSION 

CONVERTIBLE NOTE PURCHASE AND SECURITY AGREEMENT 

This Convertible Note Purchase and Security Agreement (as amended, restated, amended and restated, supplemented or otherwise modified from
time to time, this “Agreement”) is entered into as of August 11, 2017 (the “ Effective Date”) by and among Kodiak Sciences Inc., a Delaware corporation (the “Company”), the Guarantors from time to
time party hereto, the purchasers from time to time party hereto (each a “Purchaser” and collectively, the “Purchasers”) and Baker Bros. Advisors LP, as agent and collateral agent for the Purchasers (in such
capacity, the “Designated Agent”). 
 RECITALS 

WHEREAS, the Purchasers are willing, pursuant to the terms and conditions of this Agreement, to purchase (the “Note
Purchase”) from the Company convertible senior secured promissory notes in the form attached as Exhibit A (each as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the
“Notes”) in an aggregate principal amount equal to Ten Million Dollars ($10,000,000) (the “Note Purchase Amount”) which Note Purchases are, and are deemed to be, part of a single loan issued pursuant to this
Agreement; 
 WHEREAS, each Purchaser owns securities of the Company, and each Purchaser shall be entitled at any time after the Target
Financing Date (as defined below) to convert such Purchaser’s Notes into newly issued, fully paid and non-assessable shares of the Series B Preferred Stock, par value $0.0001 per share, of the Company
(the “Class B Shares”) at a price per share equal to $ 5.00 (as it may be adjusted from time to time pursuant to Section 5.6, the “Conversion Price”) on the terms and subject to the
conditions set forth herein; and 
 WHEREAS, the Notes are subject to conversion into Equity Interests of the Company on the terms and
subject to the conditions set forth herein. 
 NOW, THEREFORE, for valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto hereby agree as follows: 
 AGREEMENT 

1. DEFINITIONS. 
 1.1
Certain Defined Terms. As used in this Agreement, the following terms shall have the following respective meanings: 

“Account Control Agreement” has the meaning set forth in Section 4.10. 

“Affiliate” of any Person means (a) any other Person which, directly or indirectly, controls or is controlled by or is
under common control with such Person and (b) any officer or director of such Person. A Person shall be deemed to be “controlled by” any other Person if such Person possesses, directly or indirectly, power to vote 20% or more of the
securities (on a fully diluted basis) having ordinary voting power for the election of directors or managers or power to direct or cause the direction of the management and policies of such Person whether by contract or otherwise. Unless expressly
stated otherwise herein, no Purchaser shall be deemed an Affiliate of any Loan Party. 

 “Approved Financing” means a preferred stock financing of the Company, with the
principal purpose of raising capital, and having aggregate cash proceeds of at least $17,500,000 and less than $25,000,000, including the Outstanding Balance of the Notes and all accrued but unpaid and uncapitalized interest thereon. 

“Change of Control” means an event or series of events (i) by which the Company’s shareholders as of the Effective
Date shall cease to beneficially own and control at least 50.1% on a fully diluted basis of the economic and voting interests in the capital stock of the Company; (ii) by which any Person or group (within the meaning of the Securities Exchange
Act of 1934 and the rules of the SEC thereunder) shall beneficially own and control 50.1% or more on a fully diluted basis of the economic and voting interests in the capital stock of the Company or (iii) which constitutes a liquidation,
dissolution or winding up of the Company or a Deemed Liquidation Event (as defined in the Company’s certificate of incorporation). 

“Class B Shares” has the meaning set forth in the recitals hereto. 

“Class B Share Warrants ” means warrants exercisable for an aggregate of 500,000 of the Class B
Shares, in substantially the form attached hereto as Exhibit B, with an exercise price of $0.01 per share. 

“Collateral” has the meaning set forth in Section 4.1. 

“Collateral Documents” means, collectively, this Agreement, the Intellectual Property Security Agreements, and each of the
mortgages, collateral assignments, security agreements, pledge agreements or other similar agreements delivered to the Designated Agent pursuant to Section 4, and each of the other agreements, instruments or documents that creates or purports
to create a Lien in favor of the Designated Agent for the benefit of the Purchasers to secure the Secured Obligations. 
 “Common
Stock” means the Common Stock of the Company, par value $0.0001 per share. 
 “Company” has the meaning set forth
in the preamble hereto. 
 “Conversion Price” has the meaning set forth in the recitals hereto. 

“Designated Agent” has the meaning set forth in the preamble hereto. 

“Disqualification Events” has the meaning set forth in Section 7.5 hereto. 

“Effective Date” has the meaning set forth in the preamble hereto. 

“Equity Financing” means an equity financing of the Company after the Effective Date, with the principal purpose of raising
capital, excluding any equity offering pursuant to an employee benefit plan or the issuance of equity interests to service providers in the ordinary course of business consistent with past practice. 

  
 2 

 “Equity Interests” means (a) all shares of capital stock (whether
denominated as common stock or preferred stock), equity interests, beneficial, partnership or membership interests, joint venture interests, participations or other ownership or profit interests in, or equivalents (regardless of how designated) of,
a Person (other than an individual), whether voting or non-voting, and (b) all securities convertible into or exchangeable for any security described in clause (a) or any other security described in
this clause (b) and all warrants, options or other rights to purchase, subscribe for or otherwise acquire any such security, whether or not presently convertible, exchangeable or exercisable. For the avoidance of doubt, “Equity
Interests” shall not include debt instruments that are convertible into Equity Interests. 
 “Event of Default” has
the meaning set forth in Section 9. 
 “GAAP” means generally accepted accounting principles as in effect in the
United States of America. 
 “Guarantor ” shall mean each wholly-owned domestic Subsidiary of the Company and any person
that from time to time delivers a joinder to this Agreement with respect to the obligations of the Company under the Note Documents. 

“Indebtedness” of any Person means without duplication, (a) all indebtedness of such Person for borrowed money,
(b) all indebtedness evidenced by bonds, debentures, notes or similar instruments, (c) all obligations of such Person as lessee under capital leases which have been or should be recorded as liabilities on a balance sheet of such Person in
accordance with GAAP, (d) all obligations of such Person to pay the deferred purchase price of property or services (excluding trade accounts payable in the ordinary course of business), (e) all indebtedness secured by a Lien on the property of
such Person, whether or not such indebtedness shall have been assumed by such Person (with the amount thereof being measured as the fair market value of such property), (f) all obligations, contingent or otherwise, with respect to letters of credit
(whether or not drawn), banker’s acceptances and surety bonds issued for the account of such Person, (g) all obligations for which such Person is obligated pursuant to any interest rate swap, interest rate cap, interest rate collar or
other interest rate hedging agreement or derivative agreements or arrangements and, (h) all guarantees or other contingent obligations of such Person in respect of any of the foregoing. 

“Investment” means, with respect to any Person, (a) the purchase or other acquisition of any debt or equity security of
any other Person, (b) the making of any loan, advance or capital contribution to any other Person, (c) becoming obligated with respect to a guarantees or other contingent obligation in respect of obligations of any other Person or
(d) the acquisition of (i) all or substantially all of the property of, or a line of business or division of, another Person or (ii) at least a majority of the voting of another Person, in each case whether or not involving a merger
or consolidation with such other Person. 

  
 3 

 “Lien” means any mortgage, deed of trust, or pledge, security interest,
hypothecation, assignment, assigned deposit, arrangement, encumbrance, encroachment, lien (statutory or otherwise), claim, option, reservation or defect of any kind, or preference, or priority, or other security agreement or preferential arrangement
of any kind of or nature whatsoever (including, without limitation, any conditional sale or other title retention agreement, any financing statement under the UCC, or under the comparable law of any other jurisdiction). 

“Loan Party” means the Company and any Guarantor. 

“Maturity Date” has the meaning set forth in Section 3.1. 

“ Note Documents” means this Agreement, any Notes, any Collateral Document, any joinder and any other agreements or documents
executed and delivered in connection with the foregoing. 
 “Outstanding Balance” has the meaning set forth in
Section 3.2. 
 “Permitted Liens” means (a) Liens created hereunder in favor of the Designated Agent, for the
benefit of the Purchasers, (b) Liens securing indebtedness permitted pursuant to Section 8.2(b)(iii) below and (c) Liens securing the payments of taxes, assessments and governmental charges or levies that are not delinquent;
(d) bankers Liens’, rights of setoff and similar Liens incurred on deposits made in the ordinary course of business; (e) statutory liens of landlords and deposits in the ordinary course of business consistent with past practices to
secure the performance of leases; (f) the claims of materialmen, mechanics, carriers, warehousemen, processors or landlords for labor, materials, supplies or rentals incurred in the ordinary course of business; (g) deposits or pledges made
in the ordinary course of business in connection with, or to secure payment of, obligations under workers’ compensation, unemployment insurance and other types of social security or similar legislation, or to secure the performance of bids,
trade contracts and leases (other than Indebtedness), statutory obligations, surety bonds (other than bonds related to judgments or litigation), performance bonds and other obligations of a like nature incurred in the ordinary course of business;
(h) Liens securing judgments for the payment of money not constituting an Event of Default, or securing appeal or other surety bonds relating to such judgments; (i) any interest or title of a licensor, sublicensor, lessor or sublessor with
respect to any assets under any non-exclusive license or lease agreement entered into in the ordinary course of business which do not secure any Indebtedness; and (j) Liens arising from precautionary UCC
financing statements or similar filings made in respect of operating leases entered into by the Company or any of its Subsidiaries. 

“Person” means any natural person, corporation, limited liability company, trust, joint venture, association, company,
partnership, governmental authority or other entity. 
 “Purchasers” has the meaning set forth in the preamble hereto. 

“Qualified Financing” means a preferred stock financing of the Company after the Effective Date, with the principal purpose
of raising capital, and having aggregate cash proceeds of at least $25,000,000, including the Outstanding Balance of the Notes and all accrued but unpaid and uncapitalized interest thereon. 

“Qualified Financing Price” has the meaning set forth in Section 5.2. 

  
 4 

 “Qualified Financing Shares” has the meaning set forth in Section 5.2. 

“Requisite Purchasers” means Purchasers holding at least 75% of the Outstanding Balance, in the aggregate, of all Notes
issued under this Agreement. 
 “Secured Obligations” means all money, debts, obligations and liabilities which now are or
have been or at any time hereafter may be or become due, owing or incurred by the Company to the Designated Agent or any Purchaser, whether direct or indirect, absolute or contingent, due or to become due, or now existing or hereafter incurred, and
which, in all instances, arise under, out of, or in connection with this Agreement, any Note, any other Note Document, whether on account of principal, interest (including, without limitation, interest accruing on the Note and interest accruing
after the filing of any petition in bankruptcy, or the commencement of any insolvency, reorganization or like proceeding, relating to the Company, whether or not a claim for post-filing or post-petition interest is allowed in such proceeding),
reimbursement obligations, fees, indemnities, costs, expenses, or otherwise; provided, that for the avoidance of doubt, the Secured Obligations shall not include any obligations of the Company or its Subsidiaries arising out of or in
connection with any obligations under any equity documents, including, without limitation, any equity benefits plan, any equities issued pursuant to an employee benefit plan or to service providers in the ordinary course of business, the
Stockholders Agreements, the Company’s certificate of incorporation as amended from time to time and/or any document or agreement evidencing the Class B Share Warrants. 

“Subsidiary” of a Person means a corporation, partnership, joint venture, limited liability company or other business entity
of which a majority of the shares of securities or other interests having ordinary voting power for the election of directors or other governing body are at the time beneficially owned, or the management of which is otherwise controlled (as
determined in accordance with GAAP), or both, by such Person. 
 “Stockholders Agreements” means, collectively, that
certain Investor Rights Agreement, that certain Voting Agreement and that certain Right of First Refusal and Co-Sale Agreement, each dated as of September 8, 2015 and as amended, restated, amended and
restated or otherwise modified from time to time, by and among the Company, the stockholders party thereto and the warrantholders party thereto. 

“Target Financing Date” means January 31, 2018. 

“UCC” means the Uniform Commercial Code as in effect on the date hereof in the relevant jurisdiction and as amended from time
to time hereafter. 
 2. NOTE PURCHASE. On the Effective Date, the Company will issue, and the Purchasers will purchase, Notes
in an aggregate amount equal to the Note Purchase Amount, subject to the terms and conditions set forth in this Agreement. 
 3. TERM;
INTEREST; REPAYMENT; PREPAYMENT. 
 3.1 Term. The Notes and all accrued and unpaid interest thereon and any and all other sums
payable to the Purchasers hereunder shall be due and payable in full on the earliest to occur of (x) December 1, 2020, (y) the date of the consummation of a Change of Control and (z) the date of any acceleration of the Notes in
accordance with Section 9 (the “Maturity Date”). 

  
 5 

 3.2 Interest; Repayment. Interest on the unpaid principal balance of the Notes (such
balance as increased as provided in this Section 3.2, the “Outstanding Balance”) will accrue from October 1, 2017 at the rate of two and a half percent (2.5%) per month, calculated on the basis of a 360 day year and actual
days elapsed. Accrued interest shall be added to the Outstanding Balance on a monthly basis on the last day of each calendar month, commencing on October 31, 2017, and no such accrued interest shall be due and payable prior to the Maturity
Date. To the extent not previously converted pursuant to Section 5 hereof, the Company will repay the Outstanding Balance plus all accrued and unpaid interest thereon on the Maturity Date. 

4. COLLATERAL 
 4.1
Security Interest. This Agreement constitutes a “security agreement” within the meaning of the UCC. In order to secure payment and performance of the Secured Obligations, each Loan Party hereby grants, collaterally assigns, and
pledges to the Designated Agent, for the benefit of the Purchasers, a first-priority security interest in and Lien on all of such Loan Party’s right, title, estate, claim and interest in and to any or all of the items listed on Exhibit C
to this Agreement (collectively, the “Collateral”). 
 4.2 Care of Collateral. The Designated Agent shall have the
right, but not the obligation, at any time an Event of Default exists, to pay any taxes or levies on or with respect to the Collateral, which payment shall be made for the account of Company and shall constitute part of the Secured Obligations. 

4.3 Financing Statements. At the request of the Designated Agent, each Loan Party will promptly cooperate with the Designated Agent in
filing such financing statements, continuation statements, assignments, certificates and other documents with respect to the Collateral, pursuant to the applicable UCC and otherwise, as the Designated Agent may reasonably request in order to enable
the Designated Agent to perfect and from time to time to renew the security interest granted, all in form satisfactory to the Designated Agent, and the Company will pay the costs of filing the same in all public offices within the United States
where the Designated Agent deems necessary or reasonably desirable. 
 4.4 Impairment of Collateral. No impairment of, injury to, or
loss or destruction of any of the Collateral shall relieve any Loan Party of any of the Secured Obligations, except as may be specifically provided otherwise herein. 

4.5 Return of Collateral. Upon payment or conversion in full of the Notes and any other amounts due hereunder, the Designated Agent
shall promptly release its security interest in, and return to the Loan Parties all Collateral hereunder. 
 4.6 Further Assurances.
Each Loan Party agrees that at any time and from time to time, at its expense, such Loan Party will promptly execute and deliver all further instruments and documents, and take all further action that the Designated Agent may reasonably request, in
order to perfect and protect the security interests granted or purported to be granted hereby and to enable the Designated Agent or any Purchaser to exercise and enforce its rights and remedies hereunder with respect to any Collateral, which
instruments and documents shall include, without limitation, any and all necessary or appropriate filings with the U.S. Patent and Trademark Office. 

  
 6 

 4.7 Designated Agent Appointed
Attorney-in-Fact. Subject to Section 4.8, each Loan Party hereby irrevocably appoints the Designated Agent as such Loan Party’s attorney-in-fact, with full authority in the place and stead of such Loan and in its name or otherwise, from time to time in the Designated Agent’s discretion and without notice to the Loan Party, to take any
action and to execute any instrument which the Designated Agent may deem reasonably necessary or advisable to accomplish the purposes of this Agreement and to perfect or continue the perfection of any security interest, including without limitation,
to receive, endorse and collect all instruments made payable to the Loan Party representing any interest payment, principal payment or other payment in respect of the Collateral or any part thereof and to give full discharge for the same, and to
transfer the Collateral into the name of the Designated Agent or a third party as the UCC permits, when and to the extent permitted by this Agreement. The Designated Agent’s appointment as attorney in fact, and all of Designated Agent’s
rights and powers, coupled with an interest, are irrevocable until all Secured Obligations have been fully repaid and performed. 
 4.8
Designated Agent May Perform. Upon the occurrence and during the continuance of an Event of Default, the Designated Agent may exercise the power of attorney granted to it in Section 4.7 to (but shall not be obligated and shall have no
liability to any Person for failure to) itself perform, or cause performance of, this Agreement, and the reasonable expenses of the Designated Agent incurred in connection therewith shall be payable by the Company; provided that the
Designated Agent may exercise the power of attorney to sign any Loan Party’s name on any documents necessary to perfect or continue the perfection of any security interest regardless of whether an Event of Default has occurred. 

4.9 Intellectual Property. As to Collateral in the form of intellectual property (“Intellectual Property Collateral”):

 (a) With respect to each item of the Intellectual Property Collateral, each Loan Party agrees to take, at its expense, all
commercially reasonable steps, including, without limitation, in the U.S. Patent and Trademark Office, the U.S. Copyright Office and any other governmental authority within the United States, to (i) maintain the validity and enforceability of
such Intellectual Property Collateral and maintain such Intellectual Property Collateral in full force and effect, and (ii) pursue the registration and maintenance of each patent, trademark, or copyright registration or application, now or
hereafter included in such Intellectual Property Collateral. No Loan Party shall, without the written consent of the Designated Agent, discontinue use of or otherwise abandon or fail to pursue the registration or maintenance of any Intellectual
Property Collateral, other than Intellectual Property Collateral which is not material to the business of the Loan Parties, taken as a whole. 

  
 7 

 (b) In the event that a Loan Party becomes aware that an item of the Intellectual
Property Collateral which is material to the business of the Loan Parties, taken as a whole, is being infringed or misappropriated by a third party, the Company shall promptly notify the Designated Agent and shall take such actions, at its expense,
as the Company or the Designated Agent deems reasonable and appropriate under the circumstances to protect or enforce such Intellectual Property Collateral, including, without limitation, suing for infringement or misappropriation and for an
injunction against such infringement or misappropriation. 
 (c) Each Loan Party agrees to execute and deliver an agreement,
in substantially the form set forth in Exhibit D hereto (an “Intellectual Property Security Agreement”), for recording the security interest granted hereunder to the Designated Agent, for the benefit of the Purchasers, in
such Intellectual Property Collateral with the U.S. Patent and Trademark Office, the U.S. Copyright Office and any other governmental authorities within the United States necessary to perfect the security interest hereunder in such Intellectual
Property Collateral. 
 (d) Each Loan Party agrees that should it obtain an ownership interest in any items that would
constitute Intellectual Property Collateral that is not on the date hereof a part of the Intellectual Property Collateral (“After-Acquired Intellectual Property”) (i) the provisions of this Agreement shall automatically apply
thereto, and (ii) any such After-Acquired Intellectual Property and, in the case of trademarks, the goodwill symbolized thereby, shall automatically become part of the Intellectual Property Collateral subject to the terms and conditions of this
Agreement with respect thereto. The Company shall give prompt written notice to the Designated Agent identifying the After-Acquired Intellectual Property, and each applicable Loan Party shall execute and deliver to the Designated Agent an
Intellectual Property Security Agreement covering such After-Acquired Intellectual Property, which Intellectual Property Security Agreement shall be recorded with the U.S. Patent and Trademark Office, the U.S. Copyright Office and any other
governmental authorities within the United States necessary to perfect the security interest hereunder in such After-Acquired Intellectual Property. 

4.10 Deposit Accounts. Subject to Section 8.1(h), no Loan Party shall deposit, or cause or permit to be deposited, any cash,
checks, drafts or similar items in any deposit accounts other than those with respect to which such Loan Party shall have delivered to the Designated Agent a fully executed account control agreement reasonably acceptable to the Designated Agent
(each, an “Account Control Agreement”). Until so deposited all such payments shall be held in trust by the Loan Parties for the Designated Agent and shall not be commingled with any other funds or property of any Person. Unless an
Event of Default exists, the Designated Agent will not give notice to any depositary bank pursuant to an Account Control Agreement requiring such bank to disregard further instructions from the applicable Loan Parties. Notwithstanding the foregoing,
an Account Control Agreement shall not be required for a payroll account provided that (a) such payroll account is maintained in the ordinary course of business, (b) no monies other than monies to be used to pay payroll shall be kept in
such payroll accounts, and (c) the payroll account shall not be funded more than four (4) Business Days prior to the applicable payroll payment date or in an amount greater than the anticipated payroll. 

  
 8 

 4.11 Pledged Stock. Any Collateral constituting Equity Interests which are represented by
certificates (the “Pledged Interests”) shall be promptly delivered to the Designated Agent, together with irrevocable stock powers or similar transfer instruments, executed in blank, for such Pledged Interests. While an Event of
Default exists, the Designated Agent shall have the right to vote the Pledged Interests or other Collateral or give consents, waivers or ratifications in respect thereof. Each Loan Party shall deliver to the Designated Agent all non-cash distributions made on or in respect of the Collateral and any distributions made in connection with a liquidation or the return of capital. 

5. CONVERSION. The Outstanding Balance plus accrued interest is convertible on the following basis: 

5.1 Optional Conversion. At any time after the Target Financing Date has occurred until the Notes of such Purchaser have been fully paid
in cash or converted into preferred stock in accordance herewith, each Purchaser shall have the right to convert all or any portion of the Notes held by such Purchaser into a number of Class B Shares equal to (i) the Outstanding Balance of
the Notes to be converted plus any accrued but unpaid and uncapitalized interest thereon divided by (ii) the Conversion Price. Upon each such conversion, the Purchaser receiving Class B Shares shall be entitled to the rights and
privileges, including, without limitation, voting rights, registration rights, liquidation preferences and other rights, with respect to such Class B Shares as set forth in the Company’s certificate of incorporation. The Purchasers shall
exercise such right to convert by (i) surrendering to the Company the Note to be converted, (ii) delivering an executed conversion notice in substantially the form attached as Exhibit A to such Note and (iii) if such Purchaser is not party
to the Stockholders Agreements, delivering joinders or such other documents as are reasonably necessary to become a party to the Stockholders Agreements. The Company shall deliver the Class B Shares to a Purchaser within five business days
after such Purchaser complies with the immediately preceding sentence. 
 5.2 Automatic Conversion Upon Qualified Financing. If a
Qualified Financing occurs on or prior to the Target Financing Date, the Outstanding Balance of the Notes, plus accrued interest thereon, shall automatically be converted into a number of shares of the class of preferred stock issued in such
Qualified Financing (the “Qualified Financing Shares”) on the date that aggregate cash proceeds of $25,000,000 or greater have been received by the Company pursuant to the Qualified Financing equal to (i) the Outstanding
Balance of the Notes to be converted plus any accrued but unpaid and uncapitalized interest thereon divided by (ii) the original issue price of the Qualified Financing Shares (it being understood that such original issue price shall not exceed
a maximum price of $6.00 per share, and if such original issue price exceeds $6.00 per share, for purposes of this calculation, the original issue price shall be deemed to be $6.00 per share (in each case as adjusted pursuant to Section 5.6))
(the “Qualified Conversion Price”). The Company shall provide the Purchasers with at least ten calendar days’ prior written notice of the anticipated occurrence of any Qualified Financing and the Purchasers shall irrevocably
confirm (in writing, delivered to the Company at least three business days prior to the consummation thereof) their intention to effect the conversion in accordance with the terms hereof. The Company shall deliver the Qualified Financing Shares to
the Purchasers concurrently with consummation of the Qualified Financing. Within ten business days after request by the Company, any Purchaser that is not party to the Stockholders Agreements shall deliver joinders or such other documents as are
reasonably necessary for such Purchaser to become a party to the Stockholders Agreements. 

  
 9 

 5.3 Automatic Conversion with Requisite Purchaser Consent. If, on or prior to the Target
Financing Date, the Company consummates an Approved Financing, then upon the election of the Requisite Purchasers (in their sole discretion) pursuant to the following sentence, the Outstanding Balance of the Notes, plus accrued interest thereon,
shall automatically be converted into a number of shares of the class of preferred stock issued in such Approved Financing (the “Approved Financing Shares”) on the date that aggregate cash proceeds of $17,500,000 or greater have
been received by the Company pursuant to the Approved Financing, equal to (i) the Outstanding Balance of the Notes to be converted plus any accrued but unpaid and uncapitalized interest thereon divided by (ii) the original issue price of
the Approved Financing Shares (it being understood that such original issue price shall not exceed a maximum price of $6.00 per share, and if such original issue price exceeds $6.00 per share, for purposes of this calculation, the original issue
price shall be deemed to be $6.00 per share (in each case as adjusted pursuant to Section 5.6)) (the “Approved Conversion Price”). The Company shall provide the Purchasers with at least ten calendar days’ prior written
notice of the anticipated occurrence of any Approved Financing, and the Purchasers shall irrevocably confirm (in writing, delivered to the Company at least three business days prior to the consummation thereof) their election to effect the
conversion in accordance with the terms hereof. The Company shall deliver the Approved Financing Shares to the Purchasers concurrently with consummation of the Approved Financing. Within ten business days after request by the Company, any Purchaser
that is not party to the Stockholders Agreements shall deliver joinders or such other documents as are reasonably necessary for such Purchaser to become a party to the Stockholders Agreements. 

5.4 Repayment or Optional Conversion After Target Financing Date. If, after the Target Financing Date, the Company consummates an Equity
Financing of the Company, then the Notes will, be due and payable in full in cash on the date of consummation of such Equity Financing unless a Purchaser elects, at its option, to convert the Outstanding Balance of its Notes, plus accrued but unpaid
and uncapitalized interest thereon, into a number of shares of the class of equity interests issued in such Equity Financing (“Other Financing Shares”) equal to (i) the Outstanding Balance of the Notes to be converted plus any
accrued but unpaid and uncapitalized interest thereon divided by (ii) the original issue price of the Other Financing Shares. The Company shall provide the Purchasers with at least ten calendar days’ prior written notice of the anticipated
occurrence of any Equity Financing. The Purchasers shall exercise such right to convert by (i) surrendering to the Company the Note to be converted, (ii) delivering an executed conversion notice in substantially the form attached as
Exhibit A to such Note and (iii) if such Purchaser is not party to the Stockholders Agreements, delivering joinders or such other documents as are reasonably necessary to become a party to the Stockholders Agreements. The Company shall deliver
the Other Financing Shares to a Purchaser within five business days after such Purchaser complies with the immediately preceding sentence. 

5.5 Conversion or Repurchase Upon Change of Control. If, prior to consummation of a Qualified Financing, a Change of Control occurs,
then each Purchaser may elect, at its option, to (a) convert the Outstanding Balance of its Notes, plus accrued but unpaid and uncapitalized interest thereon, into Class B Shares at the Conversion Price or (b) require the Company to
repurchase the Notes at a repurchase price equal to 150% of the Outstanding Balance of such Notes, plus accrued but unpaid and uncapitalized interest thereon, in cash on the date of consummation of such Change of Control. The Company shall provide
the Purchasers with at least ten business days’ prior written notice of the occurrence of any Change of Control. 

  
 10 

 The Purchasers shall exercise such right to convert by, prior to the consummation of such Change of Control,
(i) surrendering to the Company the Note to be converted, (ii) delivering an executed conversion notice in substantially the form attached as Exhibit A to such Note and (iii) if such Purchaser is not party to the Stockholders
Agreements, delivering joinders or such other documents as are reasonably necessary to become a party to the Stockholders Agreements. Any such conversion shall be effective immediately prior to, but contingent upon, such Change of Control. 

5.6 Adjustment of Conversion Price. In the event of any recapitalization, stock split, stock dividend, reverse stock split, issuance of
capital stock of the Company after the date hereof, distribution by the Company upon its capital stock or similar event, the Company, and the Purchasers shall negotiate in good faith to adjust the Conversion Price or original issue price, as
applicable, to equitably preserve the value of the Notes and the value of the Equity Interests into which the Notes convert after giving effect to such recapitalization, stock split, stock dividend, reverse stock split, issuance, distribution or
similar event. 
 5.7 Reservation of Securities. The Company shall reserve, until all Notes have been fully repaid or converted into
securities in accordance with this Agreement, such Class B Shares, any Qualified Financing Shares, any Approved Financing Shares or any Other Financing Shares, as applicable, as each Purchaser is entitled to receive upon conversion of such
Purchaser’s Notes. Prior to the issuance of any Class B Shares, any Qualified Financing Shares, any Approved Financing Shares or any Other Financing Shares (or any instrument exercisable for or converted into Equity Interests) and whenever
otherwise required, the Company will amend its certificate of incorporation to ensure that there is a sufficient quantity of such Equity Interests into which each Note can be converted. 

6. REPRESENTATIONS AND WARRANTIES OF THE LOAN PARTIES. Each Loan Party hereby represents and warrants to the Purchasers on the
date hereof as follows: 
 6.1 Organization, Good Standing and Qualification. Each Loan Party is a corporation duly organized, validly
existing and in good standing under, and by virtue of, the laws of its jurisdiction of formation and has all requisite corporate power and authority to own its properties and assets and to carry on its business as now conducted and as presently
proposed to be conducted. Each Loan Party is qualified to do business as a foreign corporation in each jurisdiction where failure to be so qualified would have a material adverse effect on the financial condition, business, or operations of the Loan
Parties taken as a whole. 
 6.2 Capitalization. 

(a) Company Capitalization. The authorized capital of the Company immediately prior to the Effective Date consists of
(i) 18,753,596 shares of preferred stock, par value $0.0001 per share, of which (A) 6,253,596 shares have been designated Series A Preferred Stock, 5,593,154 of which are issued and outstanding, and (B) 12,500,000 shares have been designated Series
B Preferred Stock, 6,792,000 of which are issued and outstanding, and (ii) 28,500,000 shares of Common Stock, par value $0.0001 per share, of which 7,930,831 (including 429,322 shares subject to repurchase by the Company) are issued and outstanding.
Under (i) the Company’s 2009 Option and Profits 

  
 11 

 Interest Plan, (A) vested and unvested options to purchase 92,500 shares of Common Stock
have been granted and are currently outstanding, and (B) no Common Stock remains available for issuance, and (ii) the Company’s 2015 Stock Incentive Plan, 1,722,018 shares of Common Stock are reserved for issuance to officers,
directors, employees and consultants of the Company, 1,251,298 of which have been granted or are currently outstanding. 

(b) Options, Warrants, Reserved Shares. The Company has reserved 5,669,804 of its Class B Shares for possible
issuance upon the conversion of the Notes issued hereunder and the exercise of the Class B Share Warrants (the “Conversion Shares”). Except as described in this Section 6.2, there are no options, warrants,
conversion privileges or other rights, or agreements with respect to the issuance thereof, presently outstanding to purchase any of the capital stock of the Company. Apart from the exceptions noted in this Section 6.2 and apart from repurchase
rights (a) of the Company over shares of Common Stock pursuant to customary repurchase arrangements or the Company’s organizational documents and (b) under the Stockholders Agreements, no shares (including the Conversion Shares) of
the Company’s outstanding capital stock, or stock issuable upon exercise or exchange of any outstanding options or other stock issuable by the Company, are subject to any rights of first refusal or other rights to purchase such stock, pursuant
to any agreement or commitment of the Company. 
 6.3 Subsidiaries. Except as set forth on Schedule 6.3 attached hereto, the
Company does not have any Subsidiaries, and each such Subsidiary is wholly owned (directly or indirectly) by the Company. 
 6.4 Due
Authorization; Consents. All corporate action on the part of each Loan Party and its officers, directors and stockholders necessary for (a) the authorization, execution and delivery of, and the performance of all obligations of such Loan
Party under this Agreement and the other Note Documents, (b) the authorization, issuance, execution and delivery of the Notes by the Company and (c) the authorization, issuance, reservation for issuance and delivery by the Company of all
of the equity securities issuable upon conversion of the Outstanding Balance (and the securities issuable upon conversion thereof) has been taken. This Agreement, the Intellectual Property Security Agreements and each of the Notes constitutes a
valid and binding obligation of the Loan Parties party thereto, enforceable in accordance with its terms, subject, as to enforcement of remedies, to applicable bankruptcy, insolvency, moratorium, reorganization and similar laws affecting
creditors’ rights generally and to general equitable principles. All consents, approvals and authorizations of, and registrations, qualifications and filings with, any federal or state governmental agency, authority or body, or any third party,
required in connection with the execution, delivery and performance of this Agreement, the Notes and the other Note Documents and the consummation of the transactions contemplated hereby and thereby have been obtained; provided, however, that with
respect to any required filings under Regulation D or any other federal or state securities filings, the Company will make such filings within fifteen business days after the Effective Date. 

  
 12 

 6.5 Valid Issuance of Stock. The outstanding shares of the capital stock of each Loan
Party are duly and validly issued, fully paid and non-assessable, and such shares of such capital stock, and all outstanding options and other securities of each Loan Party have been issued in full compliance
with the registration and prospectus delivery requirements of the Securities Act of 1933, as amended (the “Act”), and the registration and qualification requirements of all applicable state securities laws, or in compliance with
applicable exemptions therefrom, and all other provisions of applicable federal and state securities laws, including, without limitation, anti-fraud provisions. 

6.6 Compliance with Other Instruments. The authorization, execution and delivery of this Agreement, the issuance and delivery of the
Notes, the execution and delivery of any other Note Document and the performance of all obligations hereunder and thereunder, will not constitute or result in a breach, default or violation of any law or regulation applicable to any Loan Party or
any material term or provision of the Company’s current certificate of incorporation or bylaws (or any comparable organization document of any Loan Party) or any material agreement or instrument by which any Loan Party is bound or to which its
properties or assets are subject. 
 6.7 Investment Company Act. Neither the Company nor any other Loan Party is an “investment
company” or a company “controlled” by an “investment company” or a “subsidiary” of an “investment company”, within the meaning of the Investment Company Act of 1940. 

6.8 Ownership of Properties. 

(a) Each Loan Party and each of its Subsidiaries has valid and legal title to, or valid leasehold interests in, all property
necessary or used in the ordinary conduct of its business, except as would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the financial condition, business, or operations of the Loan Parties taken
as a whole. 
 (b) Each Loan Party owns, or is licensed or otherwise has the right to use, all intellectual property
necessary to conduct its business as currently conducted except for such intellectual property the failure of which to own or have a license or other right to use would not reasonably be expected to have, either individually or in the aggregate, a
material adverse effect on the financial condition, business, or operations of the Loan Parties taken as a whole. To the knowledge of each Loan Party, (a) the conduct and operations of the businesses of each Loan Party do not, and the
anticipated products and intellectual property applications of the Loan Parties will not, infringe upon, misappropriate, dilute or violate any intellectual property owned by any other Person and (b) no other Person has contested any right, title or
interest of any Loan Party in any Intellectual Property Collateral or any anticipated products and applications derived or expected to be derived therefrom. 

(c) The property of each Loan Party and each of its Subsidiaries is subject to no Liens other than Permitted Liens. 

6.9 Other Security Interests. No Loan Party has heretofore assigned or granted a security interest in any of the Collateral, has not
otherwise suffered or permitted to exist any Lien on the Collateral, and will not hereafter assign or grant a security interest in or suffer or permit any Lien on all or any portion of the Collateral other than Permitted Liens. 

  
 13 

 7. REPRESENTATIONS AND WARRANTIES OF PURCHASERS. Each Purchaser represents and
warrants to the Company as follows: 
 7.1 Investigation; Economic Risk. Each Purchaser acknowledges that it has had an opportunity to
discuss the business, affairs and current prospects of the Company with its officers. Each Purchaser further acknowledges having had access to information about the Company that it has requested. Each Purchaser acknowledges that it is able to fend
for itself in the transactions contemplated by this Agreement and has the ability to bear the economic risks of its investment pursuant to this Agreement. Each Purchaser further acknowledges that it has obtained its own attorneys, business advisors
and tax advisors as to legal, business and tax advice (or has decided not to obtain such advice) and has not relied on the Company for such advice. 

7.2 Purchase for Own Account. Each Note issued to each Purchaser and the securities issuable upon exercise or conversion thereof will be
acquired by such Purchaser for its own account, not as a nominee or agent, and not with a view to or in connection with the sale or distribution of any part thereof. 

7.3 Exempt from Registration; Restricted Securities. Each Purchaser understands that the sale of the Notes will not be registered under
the Act on the grounds that the sale provided for in this Agreement is exempt from registration under of the Act, and that the reliance of Holdings on such exemption is predicated in part on each Purchaser’s representations set forth in this
Agreement. Each Purchaser understands that the Notes and the securities issuable upon exercise or conversion thereof are restricted securities within the meaning of Rule 144 under the Act, and must be held indefinitely unless they are subsequently
registered or an exemption from such registration is available. 
 7.4 Accredited Investor. Each Purchaser is an “accredited
investor” within the meaning of Rule 501 of Regulation D of the Securities and Exchange Commission. 
 7.5 Foreign Investors. If
Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Internal Revenue Code of 1986, as amended), Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in
connection with any invitation to purchase the Notes or any use of this Agreement or the Stockholder Agreements, including (i) the legal requirements within its jurisdiction for the purchase of the Notes, (ii) any foreign exchange
restrictions applicable to such purchase, (iii) any government or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale or
transfer of the Notes or any equity securities which the Notes may be converted into pursuant to the terms hereof. The Company’s offer and sale and Purchaser’s acquisition of and payment for and continued beneficial ownership of the Notes
or any equity securities which the Notes may be converted into pursuant to the terms hereof will not violate any applicable securities or other laws of such Purchaser’s jurisdiction. 

  
 14 

 7.6 No “Bad Actor” Disqualification Events. Neither
(i) Purchaser, (ii) any of its directors, executive officers, other officers that may serve as a director or officer of any company in which it invests, general partners or managing members, nor (iii) any beneficial owner of the
Company’s voting equity securities (in accordance with Rule 506(d) of the Securities Act held by the Purchaser is subject to any of the “bad actor” disqualifications described in Rule 506(d)(1)(i) through (viii) under the
Securities Act (“ Disqualification Events”), except for Disqualification Events covered by Rule 506(d)(2)(ii) or (iii) or (d)(3) under the Securities Act and disclosed reasonably in advance of a Closing in writing in reasonable
detail to the Company. 
 8. COVENANTS. The following covenants shall apply so long as any Notes remain outstanding: 

8.1 Affirmative Covenants. The Company covenants, for so long as this Agreement is in effect or any Secured Obligations (other than
contingent indemnification obligations for which no claim has been asserted) remain outstanding: 
 (a) upon one business
day’s prior notice (provided no notice is required if an Event of Default has occurred and is continuing), the Designated Agent or its agents shall have the right to inspect the Collateral and to audit and copy the Company’s books and
records during the Company’s regular business hours; 
 (b) (i) the Company shall at all times insure all of the
tangible personal property Collateral and carry such other business insurance as is customary for companies similarly situated to the Company; and (ii) within 30 days after the Effective Date, all property policies will have a lender’s
loss payable endorsement showing the Designated Agent as a lender loss payee and all liability policies will show the Designated Agent as an additional insured and provide that the insurer must give the Designated Agent at least twenty
(20) days notice before canceling its policy; 
 (c) the Company will file, when due, all income and other material tax
returns and reports required by applicable law, and will pay when due, all income and other material taxes, assessments, deposits and contributions now or in the future owed (except for taxes and assessments being contested in good faith with
adequate reserves under GAAP); 
 (d) the Company will comply, in all material respects, with all applicable laws, rules and
regulations; 
 (e) as soon as available, but not later than 210 days after the end of each fiscal year, the Company will
deliver annual audited (unless the Designated Agent agrees in its reasonable discretion that such financial statements may be unaudited) and certified consolidated balance sheets and related statements of income and stockholders’ equity,
prepared in accordance with GAAP, together with a comparison in reasonable detail to the prior year’s audited financial statements; 

(f) promptly after the occurrence thereof, the Company will notify the Purchasers of the occurrence of any Event of Default or
any event which would, individually or in the aggregate, reasonably be expected to have a material adverse effect on the financial condition, business, or operations of the Loan Parties taken as a whole; 

  
 15 

 (g) the Company promptly will promptly deliver such additional information
regarding the business, financial or corporate affairs of any Loan Party or any Subsidiary thereof, or compliance with the terms of the Note Documents, as any Purchaser may from time to time reasonably request; and 

(h) within 30 calendar days after the Effective Date, the Company will deliver Account Control Agreements with respect to its
deposit accounts existing on the Effective Date for which an Account Control Agreement is required pursuant to Section 4.10. 
 8.2
Negative Covenants. Neither the Company nor any Subsidiary shall, without the prior written consent of the Designated Agent, take any of the following actions: 

(a) create, incur, assume or suffer to exist any Lien on or with respect to any of its assets constituting Collateral, whether
now owned or hereafter acquired, except Permitted Liens; 
 (b) create, incur, assume or suffer to exist any Indebtedness or
any guarantees or other contingent obligations with respect thereto, except (i) the Notes issued hereunder, (ii) debt existing on the Effective Date and disclosed to the Purchasers and (iii) other debt in an aggregate amount
outstanding not to exceed $50,000; 
 (c) merge into or consolidate with any Person or permit any Person to merge into it, or
enter into any transaction which would constitute a Change of Control, except that any Subsidiary may merge into the Company so long as the Company is the surviving entity; 

(d) sell, lease, license, transfer or otherwise dispose of (i) all or substantially all of its assets or (ii) any of
its material assets outside of the ordinary course of business; 
 (e) form any Subsidiaries or make any Investments except
for (i) Investments existing on the Effective Date, (ii) cash or cash equivalents, (iii) deposit accounts with respect to which the Company has delivered to the Designated Agent a fully executed Account Control Agreement,
(iv) extensions of trade credit in the ordinary course of business, and (v) Investments between or among the Loan Parties; 

(f) (i) declare or pay any dividends or make other distributions in respect of its Equity Interests other than dividends
payable solely in the form of additional securities and dividends by any Subsidiary of the Company to the Company or (ii) redeem or repurchase any Equity Interests of the Company other than pursuant to equity incentive agreements with service
providers giving the Company the right to repurchase shares upon the termination of services; 

  
 16 

 (g) solely with respect to the Company, issue any class or series of shares of
Equity Interests in the Company requiring any cash payment prior to the payment in full or conversion in full of the Notes, other than pursuant to any conversion of the Notes in accordance with the terms of this Agreement and in connection with an
exercise of the Class B Share Warrants; 
 (h) amend or waive (i) its certificate of incorporation, bylaws or other
organizational documents in a manner materially adverse to the Purchasers or (ii) the Stockholders Agreements other than as required in connection with this Agreement or in connection with an Equity Financing; 

(i) enter into any transaction or arrangement with any Affiliate of the Loan Party or any Subsidiary except (i) in the
ordinary course of business and pursuant to the reasonable requirements of the business of such Loan Party or such Subsidiary; provided that such transaction shall be upon fair and reasonable terms no less favorable to such Loan Party or such
Subsidiary than would be obtained in a comparable arm’s-length transaction with a Person not an Affiliate of the Company or such Subsidiary, (ii) the transactions under the Note Documents,
(iii) the Stockholders Agreements, (iv) payment of compensation and benefits (including equity incentive plans, employee benefit plans and arrangements and customary indemnities) to officers, directors and employees of the Loan Parties or
another Subsidiary as approved by the Company’s Board of Directors, (v) as permitted by Section 8.2(e) or 8.2(f) and (vi) consisting of an Equity Financing; 

(j) engage in any line of business other than the businesses engaged in on the Effective Date and businesses reasonably related
thereto; 
 (k) change its name, type of organization, jurisdiction of organization, organizational identification number or
location from those as of the Effective Date without first giving at least 10 days’ prior written notice to the Designated Agent and taking all action reasonably required by the Designated Agent for the purpose of perfecting or protecting the
security interest granted by this Agreement; or 
 (l) sell, transfer or otherwise dispose of any capital stock of any direct
or indirect Subsidiary (or cause or permit any direct or indirect Subsidiary to sell, transfer or otherwise dispose of any capital stock of any direct or indirect Subsidiary), or cause or permit any direct or indirect Subsidiary to sell, lease,
transfer, or otherwise dispose (in a single transaction or series of related transactions) of all or substantially all of the assets of such Subsidiary to a non-Affiliate. 

8.3 Use of Proceeds. The Company shall use the proceeds of the Note Purchase to fund working capital requirements of the Company and for
other general corporate purposes. No proceeds will be used to repay any existing indebtedness for borrowed money, in each case, without the prior written consent of Requisite Purchasers. No proceeds will be used for the purpose of purchasing or
carrying any margin securities or for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase any margin securities or for any other purpose not permitted by Regulations T, U or X of the Board of Governors of
the Federal Reserve System. 

  
 17 

 9. DEFAULT. 

9.1 For purposes of this Agreement, the term “Event of Default” shall mean any of the following: 

(a) any Loan Party shall fail to pay any (i) principal of or interest on any Note when the same shall be due and payable,
or (ii) any other amounts payable hereunder or under any other Note Document within three business days of the same becoming due and payable; 

(b) the Company fails to comply with its obligation to convert the Notes as described in this Agreement, and such default
continues for a period of three business days; 
 (c) (i) any Loan Party shall default under any agreement under which
any Indebtedness in an aggregate principal amount then outstanding of $50,000 or more is created in a manner entitling the holder of such Indebtedness or a trustee to accelerate the maturity of such Indebtedness or (ii) any Loan Party shall
fail to make any payment when due (after any applicable notice or grace period) under any Indebtedness in an aggregate principal amount then outstanding of $50,000 or more; 

(d) any representation or warranty made by any Loan Party under or in connection with this Agreement shall prove to have been
incorrect in any material respect when made; 
 (e) any Loan Party shall fail to perform or observe any term, covenant or
agreement contained in this Agreement, any Note, any Intellectual Property Security Agreement or any other Note Document and, in the case of the covenants and agreements set forth in Sections 4.9, 4.10, 4.11 or 8.1(b)(i), (c) or (d), such failure to
perform continues for a period of 15 business days after the earlier of (i) any Loan Party obtaining knowledge thereof or (ii) receipt by the Company of written notice thereof from the Designated Agent or any Purchaser; 

(f) the filing of a petition in bankruptcy or under any similar insolvency law by any Loan Party, the making of an assignment
for the benefit of creditors, or if any involuntary petition in bankruptcy or under any similar insolvency law is filed against any Loan Party and such petition is not dismissed within sixty (60) days after the filing thereof; or 

(g) (i) any material provision of any Note Document, at any time after its execution and delivery and for any reason other
than satisfaction in full of all the Secured Obligations, ceases to be in full force and effect; or any Loan Party or any other Person contests in any manner the validity or enforceability of any material provision of any Note Document; or any Loan
Party denies that it has any or further liability or obligation under any Note Document or purports to revoke, terminate or rescind any material provision of any Note Document; or (ii) any Collateral Document after delivery thereof shall for
any reason (other than pursuant to the terms thereof) cease to create a valid and perfected first priority Lien on any portion of the Collateral purported to be covered thereby. 

  
 18 

 9.2 After the occurrence and during the continuance of an Event of Default, the Designated Agent
may, at its option, and at the direction of the Requisite Purchasers shall, accelerate repayment of the Outstanding Balance payable (but if an Event of Default described in Section 9.2(f) occurs, the Outstanding Balance is immediately due and
payable without any action by the Designated Agent) in which case the Outstanding Balance and all accrued and unpaid interest thereon and all other amounts due hereunder and under the other Note Documents shall be due and payable immediately. After
the occurrence and during the continuance of any Event of Default, the Designated Agent, on behalf of the Purchasers, may, without notice or demand do any or all of the following: (a) settle or adjust disputes and claims directly with account
debtors for amounts, on terms and in any order that Designated Agent considers advisable; (b) notify account debtors that payments are to be made directly and exclusively to the Designated Agent; (c) make any payments and do any acts it
considers necessary or reasonable to protect its security interest in the Collateral (and the Company will reasonably cooperate with the Designated Agent accordingly); (d) ship, reclaim, recover, store, finish, maintain, repair, prepare for sale,
advertise for sale and sell or otherwise dispose the Collateral; (e) deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any control agreement or similar agreements providing control of
any Collateral; (f) exercise any other rights and remedies permitted by the UCC or other applicable law. All of the Designated Agent’s rights and remedies under this Agreement or any other agreement between Purchasers and the Company are
cumulative. The Company waives demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments,
chattel paper, and guarantees held by the Designated Agent on which the Company is liable. 
 10. CONDITIONS PRECEDENT. This
Agreement shall become effective and binding upon the parties hereto only on the Effective Date if the following conditions precedent have been satisfied: 

(a) The Purchasers shall have received (i) a counterpart of this Agreement signed on behalf of each party hereto,
(ii) a Note payable to each Purchaser signed by the Company, and (iii) an Intellectual Property Security Agreement signed by each Loan Party that owns Intellectual Property Collateral, in each case, in form and substance satisfactory to
the Purchasers; 
 (b) The Purchasers shall have received Class B Share Warrants, duly authorized, executed and
delivered by the Company, exercisable for an aggregate amount of 500,000 of the Class B Shares; 
 (c) The Purchasers
shall have received proper financing statements in form appropriate for filing under the UCC of all jurisdictions that the Designated Agent may deem reasonably necessary in order to perfect and protect the first priority liens and security interests
created hereunder covering the Collateral described herein; 

  
 19 

 (d) The Purchasers shall have received certified copies of the resolutions of the
Board of Directors of the Company approving this Agreement, the transactions contemplated hereby and each Note Document to which it is or is to be a party; 

(e) The Purchasers shall have received results of a recent lien search with respect to the Loan Parties, and such search report
shall reveal no liens on any of the Collateral other than Permitted Liens; 
 (f) The Company shall have paid or caused to be
paid by means of a deduction from the Note Purchase Amount such reasonably incurred fees and expenses of the Purchasers in connection with the negotiation and preparation of the Note Documents, including the reasonable and documented fees and
expenses of counsel to the Purchasers, up to a maximum of $100,000; 
 (g) The Company shall have filed an amendment to the
Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware; 
 (h) The Purchasers shall
have received the documents specified on the Closing Checklist attached hereto as Exhibit E and such other documents as any Purchaser shall have reasonably requested in connection with this Agreement and the other Note Documents; and 

(i) The Company shall have received, by payment of wire transfer of readily available funds to the account designated by the
Company, the Note Purchase Amount less any deduction made in accordance with Section 10(f). 
 11. GUARANTEES.

 11.1 Guarantees. 

(a) Each Guarantor hereby jointly and severally, irrevocably and unconditionally guarantees, as a primary obligor and not
merely as a surety, to each Purchaser and its successors and assigns the full and punctual payment when due and full and punctual performance within applicable grace periods of all Secured Obligations (all the foregoing being hereinafter
collectively called the “Guaranteed Obligations”). Each Guarantor further agrees that the Guaranteed Obligations may be extended or renewed, in whole or in part, without notice or further assent from each such Guarantor, and that
each such Guarantor shall remain bound under this Article 11 notwithstanding any extension or renewal of any Guaranteed Obligation. 

(b) Each Guarantor waives presentation to, demand of payment from and protest to the Company of any of the Guaranteed
Obligations and also waives notice of protest for nonpayment. Each Guarantor waives notice of any Default under this Agreement or the Notes or the Guaranteed Obligations. The obligations of each Guarantor hereunder shall not be affected by
(i) the failure of any Purchaser or the Designated Agent to assert any claim or demand or to enforce any right or remedy against the Company or any other Person under this Agreement, the Note Documents or 

  
 20 

 any other agreement or otherwise; (ii) any extension or renewal of any thereof;
(iii) any rescission, waiver, amendment or modification of any of the terms or provisions of this Agreement, the Notes or any other agreement; (iv) the release of any security held by any Purchaser or the Designated Agent for the
Guaranteed Obligations or any of them; (v) the failure of any Purchaser or the Designated Agent to exercise any right or remedy against any other guarantor of the Guaranteed Obligations; or (vi) any change in the ownership of such
Guarantor. 
 (c) Each Guarantor further agrees that its guarantee herein constitutes a guarantee of payment, performance and
compliance when due (and not a guarantee of collection) and waives any right to require that any resort be had by any Purchaser or the Designated Agent to any security held for payment of the Guaranteed Obligations. 

(d) Except as expressly set forth in this Article 11, the obligations of each Guarantor hereunder shall not be subject to any
reduction, limitation, impairment or termination for any reason, including any claim of waiver, release, surrender, alteration or compromise, and shall not be subject to any defense of setoff, counterclaim, recoupment or termination whatsoever or by
reason of the invalidity, illegality or unenforceability of the Guaranteed Obligations or otherwise (other than the defense of payment in full of the Secured Obligations). Without limiting the generality of the foregoing, the obligations of each
Guarantor herein shall not be discharged or impaired or otherwise affected by the failure of any Purchaser or the Designated Agent to assert any claim or demand or to enforce any remedy under this Agreement, the Note Documents or any other
agreement, by any waiver or modification of any thereof, by any default, failure or delay, willful or otherwise, in the performance of the obligations, or by any other act or thing or omission or delay to do any other act or thing which may or might
in any manner or to any extent vary the risk of any Guarantor or would otherwise operate as a discharge of any Guarantor as a matter of law or equity. 

(e) Except as otherwise provided herein, each Guarantor agrees that its guarantee shall remain in full force and effect until
payment in full of all the Guaranteed Obligations. Each Guarantor further agrees that its guarantee herein shall continue to be effective or be reinstated, as the case may be, if at any time payment, or any part thereof, of principal of or interest
on any Guaranteed Obligation is rescinded or must otherwise be restored by any Purchaser or the Designated Agent upon the bankruptcy or reorganization of the Company or otherwise. 

(f) In furtherance of the foregoing and not in limitation of any other right which any Purchaser or the Designated Agent has at
law or in equity against any Guarantor by virtue hereof, upon the failure of the Company to pay the principal of or interest on any Guaranteed Obligation when and as the same shall become due, whether at maturity, by acceleration, by redemption or
otherwise, or to perform or comply with any other Guaranteed Obligation, each Guarantor hereby promises to and shall, upon receipt of written demand by the Designated Agent, forthwith pay, or cause to be paid, in cash, to the Purchasers or the
Designated Agent an amount equal to the sum of (i) the unpaid principal amount of such Guaranteed Obligations, (ii) accrued and unpaid interest on such Guaranteed Obligations required under the Note Documents (but only to the extent not
prohibited by law) and (iii) all other monetary obligations of the Company to the Purchasers and the Designated Agent required under the Note Documents. 

  
 21 

 (g) Each Guarantor agrees that it shall not be entitled to any right of
subrogation in relation to the Purchasers in respect of any Guaranteed Obligations guaranteed hereby until payment in full of all Guaranteed Obligations. Each Guarantor further agrees that, as between it, on the one hand, and the Purchasers and the
Designated Agent, on the other hand, (i) the maturity of the Guaranteed Obligations guaranteed hereby may be accelerated as provided in Article 9 for the purposes of any guarantee herein, notwithstanding any stay, injunction or other
prohibition preventing such acceleration in respect of the Guaranteed Obligations guaranteed hereby, and (ii) in the event of any declaration of acceleration of such Guaranteed Obligations as provided in Article 9 of this Agreement, such
Guaranteed Obligations (whether or not due and payable) shall forthwith become due and payable by such Guarantor for the purposes of this Section 11.1. 

(h) Each Guarantor also agrees to pay any and all costs and expenses (including reasonable attorney’s fees and expenses)
incurred by the Designated Agent or any Purchaser in enforcing any rights under this Section 11.1. 
 (i) Upon request
of the Designated Agent, each Guarantor shall execute and deliver such further instruments and do such further acts as may be reasonably necessary or proper to carry out more effectively the purpose of this Agreement. 

11.2 Limitation on Liability. Any term or provision of this Agreement to the contrary notwithstanding, the maximum aggregate amount of
the Guaranteed Obligations guaranteed hereunder by any Guarantor shall not exceed the maximum amount that can be hereby guaranteed without rendering this Agreement, as it relates to such Guarantor, voidable under applicable law relating to
fraudulent conveyance or fraudulent transfer or similar laws affecting the rights of creditors generally. 
 12.
MISCELLANEOUS. 
 12.1 Governing Law; Jurisdiction; Waiver of Jury Trial. This Agreement shall be governed in all
respects by and construed in accordance with the laws of the State of New York without regard to provisions regarding choice of laws. Each of the parties hereto hereby irrevocably and unconditionally submits, for itself and its property, to the
nonexclusive jurisdiction of any New York State court or Federal court of the United States of America sitting in New York City, and any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement or
any of the other Note Documents to which it is a party, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and unconditionally agrees that all claims in respect of any such action or proceeding may
be heard and determined in any such New York State court or, to the fullest extent permitted by law, in such Federal court. Each of the Company, the Designated Agent and the Purchasers irrevocably waives all right to trial by jury in any action,
proceeding or counterclaim (whether based on contract, tort or otherwise) arising out of or relating to any of the Note Documents or the actions of the Designated Agent or any Purchaser in the negotiation, administration, performance or enforcement
thereof. 

  
 22 

 12.2 Successors and Assigns. 

(a) Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon,
the successors and assigns of the parties hereto. Without the prior written consent of the Requisite Purchasers, the Company may not assign any of its rights or obligations under this Agreement, any Note, any Intellectual Property Security Agreement
or any other Note Document, and any such purported assignment shall be void. Each Purchaser, so long as no Event of Default has occurred and is continuing, with the consent of the Company (not to be unreasonably withheld), may assign or grant a
participation in its Note or its rights and obligations hereunder or under any Note; provided, that (i) no such consent shall be required in connection with any assignment to another Purchaser, an Affiliate of a Purchaser or any
shareholder of Holdings, (ii) with respect to any assignment, Purchaser or any registered assign, as applicable, shall provide to the Company the relevant documentation effecting the assignment and, for the avoidance of doubt, no such
assignment shall be effective until recorded in the Register in accordance with Section 12.2(b) and (iii) with respect to any grant of a participation, the Purchaser or registered assign that grants such participation shall, acting solely
for this purpose as a non-fiduciary agent of the Company, maintain a register on which it enters the name and address of the participant and the principal amounts (and stated interest) of the
participant’s interest in the Note. 
 (b) The Company shall maintain a copy of the assignment documentation provided to
it by any Purchaser (or any registered assign) and a register for the recordation of the names and addresses of the Purchasers, and the principal amounts (and stated interest) of each Note owing to each Purchaser (or any registered assign) pursuant
to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive absent manifest error, and the Company and each Purchaser (and registered assign) shall treat each Person whose name is recorded
in the Register pursuant to the terms hereof as a Purchaser hereunder for all purposes of this Agreement. The Register shall be available for inspection by any Purchaser (or registered assign) at any reasonable time and from time to time upon
reasonable prior notice). 
 12.3 Entire Agreement. This Agreement, the Notes, the Collateral Documents, the other Note Documents and
the Exhibits and Schedules hereto and thereto (all of which are hereby expressly incorporated herein by this reference) constitute the entire understanding and agreement between the parties with regard to the subjects hereof and thereof. 

12.4 Notices. All notices, requests, waivers and other communications made pursuant to this Agreement shall be in writing and shall be
deemed delivered, given and received when delivered (by hand, by registered mail, by courier or express delivery service, by e-mail or by facsimile) to the address,
e-mail address or facsimile telephone number set forth beneath the name of such party on its signature page to this Agreement (or to such other address, e-mail address
or facsimile telephone number as such party will have specified in a written notice given to the other parties hereto). 

  
 23 

 12.5 Amendments and Termination. Any term of this Agreement and any other Note Document
may be amended only with the written consent of the Company, the Designated Agent and the Requisite Purchasers. However, no amendment may, without the consent of all affected Purchasers (a) reduce the percentage of Purchasers required to take
or approve any action hereunder or thereunder; (b) reduce the amount or change the time of payment of any amount owing or payable with respect to any Note or change the rate of interest or the manner of calculation of interest payable with
respect to any Note; (c) release the securities interest granted in respect of all or substantially all of the Collateral for the Notes, or modify the manner of payment or the order of priorities in which payments or distributions hereunder
will be made as between the Purchasers and the Company or as among the Purchasers; (d) alter or modify in any respect, or waive, the provisions with respect to the conversion or redemption of the Notes; or (e) consent to any assignment of
the Company’s rights under the Note Documents. The Collateral Documents shall terminate automatically upon the conversion of the Notes in full pursuant to the terms hereof or when the Secured Obligations (other than contingent indemnification
obligations for which no claim has been asserted) have been paid in full. 
 12.6 Titles and Subtitles. The titles of the sections and
clauses of this Agreement are for convenience of reference only and are not to be considered in construing this Agreement. 
 12.7
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. Delivery by telecopier or
e-mail of an executed counterpart of a signature page shall be effective as delivery of an original executed counterpart. 

12.8 Severability. Should any provision of this Agreement be determined to be illegal or unenforceable, such determination shall not
affect the remaining provisions of this Agreement. 
 12.9 Expenses. The Company agrees to reimburse the Designated Agent on demand
for the reasonable costs and expenses of one counsel for the Designated Agent actually incurred in connection with the preparation, execution, delivery, administration, modification and amendment of, or any consent or waiver under, the Note
Documents; provided, that the Company’s obligation to pay costs and expenses of the Designated Agent (including, without limitation, the reasonable costs and expenses of counsel thereof) in connection with the preparation, execution and
delivery of this Agreement, the Notes and the other Note Documents on or prior to the date hereof shall be subject to the limit set forth in Section 10(f); and (ii) all costs and expenses of the Designated Agent and each Purchaser in
connection with the enforcement of the Note Documents, whether in any action, suit or litigation, or any bankruptcy, insolvency or other similar proceeding affecting creditors’ rights generally (including the reasonable fees and expenses of
counsel for the Designated Agent and each Purchaser with respect thereto). 
 12.10 Agent. Each of the Purchasers hereby irrevocably
appoints the Designated Agent as its agent, and the Designated Agent accepts such appointment, and each of the Purchasers authorizes the Designated Agent to take such actions on its behalf and to exercise such powers as are delegated to the
Designated Agent by the terms of the Note Documents, 

  
 24 

 together with such actions and powers as are reasonably incidental thereto. Without limiting the generality of
the foregoing, the Designated Agent is hereby expressly authorized to execute any and all documents (including releases) with respect to the Collateral and the rights of the Purchasers with respect thereto, as contemplated by and in accordance with
the provisions of this Agreement and the other Note Documents. Without limiting the generality of the foregoing, the Designated Agent shall have the sole and exclusive right and authority (to the exclusion of the Purchasers), and is hereby
authorized by the Purchasers as provided in this Agreement and the other Note Documents or as directed in writing by the Requisite Purchasers, to take and exercise all actions in connection with the Collateral and any other exercise of remedies
hereunder or thereunder. None of the Designated Agent or any of its directors, officers, employees or agents shall (a) be liable for any action taken or omitted to be taken by any of them under or in connection with this Agreement or any other
Note Document or the transactions contemplated hereby (except to the extent resulting from its own gross negligence or willful misconduct as determined in a final non- appealable judgment by a court of
competent jurisdiction), or (b) be responsible in any manner to any Purchaser for any recital, statement, representation or warranty made by any Loan Party or Affiliate of any Loan Party, or any officer thereof, contained in this Agreement or
in any other Note Document, or in any certificate, report, statement or other document referred to or provided for in, or received by the Designated Agent under or in connection with, this Agreement or any other Note Document, or the validity,
effectiveness, genuineness, enforceability or sufficiency of this Agreement or any other Note Document (or the creation, perfection or priority of any Lien or security interest therein), or for any failure of any Loan Party or any other party to any
Note Document to perform its obligations hereunder or thereunder. The Designated Agent shall not be under any obligation to the Purchasers to ascertain or to inquire as to the observance or performance of any of the agreements contained in, or
conditions of, this Agreement or any other Note Document, or to inspect the properties, books or records of any Loan Party or Affiliate of any Loan Party. 

12.11 Allocation of Payments. The Purchasers acknowledge that the Notes are pari passu obligations against each of the other
Notes. Each payment of interest or principal on the Notes shall be allocated among all of the Notes at the time outstanding in proportion, as nearly as practicable, to the respective unpaid balances of principal outstanding thereunder. If any
Purchaser shall, by exercising any right of setoff or counterclaim or otherwise, obtain payment in respect of any principal of or interest under any of his, her or its Notes or other obligations hereunder in an amount in excess of his, her or its
pro rata share thereof as provided herein, then such Purchaser shall forthwith pay such excess to the Designated Agent which amount the Designated Agent shall thereupon pay to the Purchasers on a pro rata basis. 

12.12 Interest Rate Limitation. Notwithstanding anything to the contrary contained in any Note Document, the interest paid or agreed to
be paid under the Note Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable Law (the “Maximum Rate”). If any Purchaser shall receive interest in an
amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal of the Notes or, if it exceeds such unpaid principal, refunded to the Company. In determining whether the interest contracted for, charged, or received by
the Purchasers exceeds the Maximum Rate, such Person may, to the extent permitted by applicable law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b) exclude voluntary prepayments
and the effects thereof, and (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the obligations hereunder. 

  
 25 

 12.13 Certain Tax Matters. Any and all payments by or on account of any obligation of the
Company under the Notes or this Agreement shall be made without deduction or withholding for any taxes, levies, imposts, duties, deductions, withholdings or assessments, fees or other charges imposed by any governmental authority, including any
interest, additions to tax or penalties applicable thereto (“Taxes”), except as required by applicable law. If the Company is required by applicable law to withhold or deduct any Taxes from any such payment, then the Company shall
withhold or deduct such Taxes, the Company shall timely pay the full amount withheld or deducted to the relevant taxing authority in accordance with applicable law, and the sum payable by the applicable Loan Party shall be increased as necessary so
that after deduction or withholding has been made for any such Tax (other than any such Tax that is an income Tax), including such deductions or withholdings applicable to additional sums payable under this Section 12.13, the applicable
recipient receive an amount equal to the sum it would have received had no such deduction or withholding been made. Notwithstanding the foregoing, the increase of the sum payable described in the immediately preceding sentence shall not be required
with respect to payments by or on account of any obligation of the Company under the Notes or this Agreement for Taxes withheld or deducted from such payments (A) to the extent such Taxes result from the failure of the applicable recipient to
provide to the Company (i) a valid properly executed IRS Form W-9 (if such recipient is a U.S. person for U.S. federal income tax purposes) or (ii) a valid properly executed appropriate IRS Form W-8 (if such recipient is not a U.S. person for U.S. federal income tax purposes) establishing a complete exemption from U.S. federal tax withholding to the extent it is legally entitled to do so or (B) in the
case of a Purchaser (or registered assign) that is not a U.S. person for U.S. federal income tax purposes, to the extent such Taxes are U.S. federal withholding Taxes imposed on amounts payable to or for the account of such person with respect to an
applicable interest in a Note pursuant to a law in effect on the date on which (i) such person acquires such interest in the Note or (ii) such person changes its lending office, except in each case to the extent that amounts with respect
to such Taxes were payable either to such person’s assignor immediately before such person became a party hereto or to such person immediately before it changed its lending office. The Company agrees to pay any and all stamp, court or
documentary, intangible, recording, filing or similar Taxes that arise in respect of this Agreement or the Note. 
 12.14 ORIGINAL ISSUE
DISCOUNT LEGEND. THE NOTES HAVE BEEN ISSUED WITH ORIGINAL ISSUE DISCOUNT FOR UNITED STATES FEDERAL INCOME TAX PURPOSES. THE ISSUE PRICE, AMOUNT OF ORIGINAL ISSUE DISCOUNT, ISSUE DATE AND YIELD TO MATURITY OF THE NOTES MAY BE OBTAINED BY WRITING
TO THE DESIGNATED AGENT AT ITS ADDRESS AS SPECIFIED IN SECTION 12.4 OF THIS AGREEMENT. 
 [Signature page follows.] 

  
 26 

 IN WITNESS WHEREOF, the parties have executed this Convertible Note Purchase and Security
Agreement to be effective as of the date first above written. 
  

			
	KODIAK SCIENCES INC.
		
	By:	 	 /s/ Victor Perlroth, M.D.

		 	Name: Victor Perlroth, M.D.
		 	Title: Chairman and CEO
	
	Address: 2361 Hanover Street
		 	        Palo Alto California 94304
	
	KODIAK SCIENCES FINANCING CORPORATION
		
	By:	 	 /s/ Victor Perlroth, M.D.

		 	Name: Victor Perlroth, M.D.
		 	Title: Authorized Signatory
	
	Address: 2361 Hanover Street
		 	        Palo Alto California 94304

 [Signature Page to Convertible Note Purchase and Security Agreement] 

 
			
	BAKER BROS. ADVISORS LP,
	as the Designated Agent
		
	By:	 	 /s/ Scott Lessing

		 	Scott Lessing
		 	President
	
	Address Before November 1, 2017:
		 	        667 Madison Avenue, 21st Floor
		 	        New York, NY 10065
		 	        Attn: Scott Lessing
	
	Address as of November 1, 2017:
		 	        860 Washington St., 10th Floor
		 	        New York, NY 10014
		 	        Attn: Scott Lessing

 [Signature Page to Convertible Note Purchase and Security Agreement] 

 
			
	667, L.P.,
	as a Purchaser
	
	By: BAKER BROS. ADVISORS LP,
	management company and investment adviser to 667, L.P., pursuant to authority granted to it by Baker Biotech Capital, L.P., general partner to 667, L.P., and not as the general partner.
		
	By:	 	 /s/ Scott Lessing

	Scott Lessing
	President
	
	Address before November 1, 2017:
		 	         c/o Baker Bros. Advisors LP

        667 Madison Avenue, 21st Floor

		 	        New York, NY 10065
		 	        Attn: Scott Lessing
	
	Address as of November 1, 2017:
		 	         c/o Baker Bros. Advisors LP

        860 Washington St., 10th Floor

		 	        New York, NY 10014
		 	        Attn: Scott Lessing

 [Signature Page to Convertible Note Purchase and Security Agreement] 

 
			
	BAKER BROTHERS LIFE SCIENCES, L.P.,
	as a Purchaser
	
	By: BAKER BROS. ADVISORS LP,
	management company and investment adviser to Baker Brothers Life Sciences, LP., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner to Baker Brothers Life Sciences,
L.P., and not as the general partner.
		
	By:	 	 /s/ Scott Lessing

		 	Scott Lessing
		 	President
	
	Address before November 1, 2017:
		 	         c/o Baker Bros. Advisors LP

        667 Madison Avenue, 21st Floor

		 	        New York, NY 10065
		 	        Attn: Scott Lessing
	
	Address as of November 1, 2017:
		 	         c/o Baker Bros. Advisors LP

        860 Washington St., 10th Floor

		 	        New York, NY 10014
		 	        Attn: Scott Lessing

 [Signature Page to Convertible Note Purchase and Security Agreement] 

 
			
	DUSTIN A. MOSKOVITZ TRUST,
	as a Purchaser
		
	By:	 	 /s/ Dustin A. Moskovitz

		 	Name: Dustin A. Moskovitz
		 	Title: Trustee
		
	Address:	 	        394 Pacific Ave, 2nd Floor
		 	        San Francisco, CA 94111

 [Signature Page to Convertible Note Purchase and Security Agreement] 

 
			
	 MACRO CONTINENTAL, INC.,
 as
a Purchaser

		
	By:	 	 /s/ Carlos A. Gonzalez May

		 	Name: Carlos A. Gonzalez May
		 	Title: Director
		
	Address:	 	        c/o Rivas Capital LLC
		 	        222 Third St., Ste 3211
		 	        Cambridge, MA 02142

 [Signature Page to Convertible Note Purchase and Security Agreement] 

 
			
	SIGMA EMERGING MARKETS LTD.,
	as a Purchaser
		
	By:	 	 /s/ Rafael Urquia II

		 	Name: Rafael Urquia II
		 	Title: Secretary
		
	Address:	 	        OMC Chambers, Wickhams Cay 1
		 	        Road Town, Tortola
		 	        British Virgin Islands
		 	        Attn.: Mr. Jaime J. Montealegre

 [Signature Page to Convertible Note Purchase and Security Agreement] 

 SCHEDULE 6.3 

Subsidiaries 
 Kodiak Sciences
Financing Corporation 
 Kodiak Sciences GmbH 

  
 Schedule 6.3-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00287-of-00352.parquet"}]]